WO2013120481A2 - Use of an agent for stimulating the gene expression of antimicrobial peptides (amp) - Google Patents
Use of an agent for stimulating the gene expression of antimicrobial peptides (amp) Download PDFInfo
- Publication number
- WO2013120481A2 WO2013120481A2 PCT/DE2013/100038 DE2013100038W WO2013120481A2 WO 2013120481 A2 WO2013120481 A2 WO 2013120481A2 DE 2013100038 W DE2013100038 W DE 2013100038W WO 2013120481 A2 WO2013120481 A2 WO 2013120481A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agent
- purine
- agent according
- zinc
- skin
- Prior art date
Links
- 102000044503 Antimicrobial Peptides Human genes 0.000 title claims description 17
- 108700042778 Antimicrobial Peptides Proteins 0.000 title claims description 17
- 230000014509 gene expression Effects 0.000 title claims description 7
- 230000004936 stimulating effect Effects 0.000 title claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 63
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims abstract description 17
- 150000003212 purines Chemical class 0.000 claims abstract description 16
- 229930002161 purine alkaloid Natural products 0.000 claims abstract description 12
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 claims abstract description 10
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims abstract description 10
- MVOYJPOZRLFTCP-UHFFFAOYSA-N 1-methyl-7H-xanthine Chemical compound O=C1N(C)C(=O)NC2=C1NC=N2 MVOYJPOZRLFTCP-UHFFFAOYSA-N 0.000 claims abstract description 8
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229960004559 theobromine Drugs 0.000 claims abstract description 5
- 229960000278 theophylline Drugs 0.000 claims abstract description 5
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 claims abstract description 3
- PFWLFWPASULGAN-UHFFFAOYSA-N 7-Methylxanthine Natural products N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229940075420 xanthine Drugs 0.000 claims abstract description 3
- -1 paraxanthin Chemical compound 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 19
- 239000000499 gel Substances 0.000 claims description 14
- 210000004209 hair Anatomy 0.000 claims description 14
- 239000002537 cosmetic Substances 0.000 claims description 9
- 239000006071 cream Substances 0.000 claims description 9
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 8
- 239000003921 oil Substances 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 239000003139 biocide Substances 0.000 claims description 6
- 239000002781 deodorant agent Substances 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 239000000419 plant extract Substances 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 5
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims description 5
- 210000004761 scalp Anatomy 0.000 claims description 5
- 239000002453 shampoo Substances 0.000 claims description 5
- 235000015961 tonic Nutrition 0.000 claims description 5
- 230000001256 tonic effect Effects 0.000 claims description 5
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 claims description 4
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 claims description 4
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 4
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 claims description 4
- 230000001166 anti-perspirative effect Effects 0.000 claims description 4
- 239000003213 antiperspirant Substances 0.000 claims description 4
- 229960001948 caffeine Drugs 0.000 claims description 4
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 229940043259 farnesol Drugs 0.000 claims description 4
- 229930002886 farnesol Natural products 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 4
- 229940101267 panthenol Drugs 0.000 claims description 4
- 235000020957 pantothenol Nutrition 0.000 claims description 4
- 239000011619 pantothenol Substances 0.000 claims description 4
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 claims description 4
- OWVLYQRCCIEOPF-QHTZZOMLSA-L zinc;(2s)-5-oxopyrrolidine-2-carboxylate Chemical compound [Zn+2].[O-]C(=O)[C@@H]1CCC(=O)N1.[O-]C(=O)[C@@H]1CCC(=O)N1 OWVLYQRCCIEOPF-QHTZZOMLSA-L 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 3
- 210000000214 mouth Anatomy 0.000 claims description 3
- 239000002324 mouth wash Substances 0.000 claims description 3
- 239000008177 pharmaceutical agent Substances 0.000 claims description 3
- 235000010384 tocopherol Nutrition 0.000 claims description 3
- 229960001295 tocopherol Drugs 0.000 claims description 3
- 229930003799 tocopherol Natural products 0.000 claims description 3
- 239000011732 tocopherol Substances 0.000 claims description 3
- 150000003751 zinc Chemical class 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 229940043810 zinc pyrithione Drugs 0.000 claims description 3
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 claims description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 3
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims description 2
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims description 2
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 claims description 2
- 235000003880 Calendula Nutrition 0.000 claims description 2
- 240000001432 Calendula officinalis Species 0.000 claims description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 2
- 244000133098 Echinacea angustifolia Species 0.000 claims description 2
- 241000510609 Ferula Species 0.000 claims description 2
- 241000378467 Melaleuca Species 0.000 claims description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 2
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims description 2
- 125000000129 anionic group Chemical group 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 229940036350 bisabolol Drugs 0.000 claims description 2
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims description 2
- 229960003260 chlorhexidine Drugs 0.000 claims description 2
- 239000010634 clove oil Substances 0.000 claims description 2
- 235000014134 echinacea Nutrition 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 150000002896 organic halogen compounds Chemical class 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 239000002884 skin cream Substances 0.000 claims description 2
- 150000005846 sugar alcohols Polymers 0.000 claims description 2
- 239000010678 thyme oil Substances 0.000 claims description 2
- 229960000716 tonics Drugs 0.000 claims description 2
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000001069 triethyl citrate Substances 0.000 claims description 2
- 235000013769 triethyl citrate Nutrition 0.000 claims description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 2
- 150000003752 zinc compounds Chemical class 0.000 claims description 2
- 239000000834 fixative Substances 0.000 claims 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 1
- 229960001325 triclocarban Drugs 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 abstract description 5
- QUNWUDVFRNGTCO-UHFFFAOYSA-N 1,7-dimethylxanthine Chemical compound N1C(=O)N(C)C(=O)C2=C1N=CN2C QUNWUDVFRNGTCO-UHFFFAOYSA-N 0.000 abstract 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 27
- 210000003491 skin Anatomy 0.000 description 16
- 239000000126 substance Substances 0.000 description 14
- 235000014113 dietary fatty acids Nutrition 0.000 description 10
- 239000000194 fatty acid Substances 0.000 description 10
- 229930195729 fatty acid Natural products 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 150000004665 fatty acids Chemical class 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 150000002191 fatty alcohols Chemical class 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 108010034929 Dermcidin Proteins 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 230000003750 conditioning effect Effects 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229940075529 glyceryl stearate Drugs 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 102000030805 Dermcidin Human genes 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 239000003906 humectant Substances 0.000 description 4
- 230000002906 microbiologic effect Effects 0.000 description 4
- 229920000570 polyether Polymers 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 3
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 108010038807 Oligopeptides Proteins 0.000 description 3
- 102000015636 Oligopeptides Human genes 0.000 description 3
- 108010009736 Protein Hydrolysates Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical class [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 239000003945 anionic surfactant Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 101150005225 dcd gene Proteins 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229940091250 magnesium supplement Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 229960005323 phenoxyethanol Drugs 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000003531 protein hydrolysate Substances 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 235000011121 sodium hydroxide Nutrition 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- NKEQOUMMGPBKMM-UHFFFAOYSA-N 2-hydroxy-2-[2-(2-hydroxy-3-octadecanoyloxypropoxy)-2-oxoethyl]butanedioic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CC(O)(C(O)=O)CC(O)=O NKEQOUMMGPBKMM-UHFFFAOYSA-N 0.000 description 2
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 2
- QWGRWMMWNDWRQN-UHFFFAOYSA-N 2-methylpropane-1,3-diol Chemical compound OCC(C)CO QWGRWMMWNDWRQN-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000035985 Body Odor Diseases 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-M alaninate Chemical compound CC(N)C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-M 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 125000005250 alkyl acrylate group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 125000000732 arylene group Chemical group 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical class OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
- 229940044199 carnosine Drugs 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 2
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000008406 cosmetic ingredient Substances 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000003500 gene array Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229940100608 glycol distearate Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 229930013032 isoflavonoid Natural products 0.000 description 2
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 2
- 235000012891 isoflavonoids Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 210000000106 sweat gland Anatomy 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 1
- NKJOXAZJBOMXID-UHFFFAOYSA-N 1,1'-Oxybisoctane Chemical compound CCCCCCCCOCCCCCCCC NKJOXAZJBOMXID-UHFFFAOYSA-N 0.000 description 1
- ZWVMLYRJXORSEP-UHFFFAOYSA-N 1,2,6-Hexanetriol Chemical compound OCCCCC(O)CO ZWVMLYRJXORSEP-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- FKKAGFLIPSSCHT-UHFFFAOYSA-N 1-dodecoxydodecane;sulfuric acid Chemical compound OS(O)(=O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC FKKAGFLIPSSCHT-UHFFFAOYSA-N 0.000 description 1
- KUTWKGLRMXBROO-UHFFFAOYSA-N 1-hexoxyoctane Chemical compound CCCCCCCCOCCCCCC KUTWKGLRMXBROO-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- HANWHVWXFQSQGJ-UHFFFAOYSA-N 1-tetradecoxytetradecane Chemical compound CCCCCCCCCCCCCCOCCCCCCCCCCCCCC HANWHVWXFQSQGJ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 1
- RYKSMKFLIHUEBL-UHFFFAOYSA-N 2-(2-ethylhexanoyloxy)propyl 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(C)OC(=O)C(CC)CCCC RYKSMKFLIHUEBL-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- LCZVSXRMYJUNFX-UHFFFAOYSA-N 2-[2-(2-hydroxypropoxy)propoxy]propan-1-ol Chemical compound CC(O)COC(C)COC(C)CO LCZVSXRMYJUNFX-UHFFFAOYSA-N 0.000 description 1
- OPJWPPVYCOPDCM-UHFFFAOYSA-N 2-ethylhexyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC OPJWPPVYCOPDCM-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- CLAHOZSYMRNIPY-UHFFFAOYSA-N 2-hydroxyethylurea Chemical compound NC(=O)NCCO CLAHOZSYMRNIPY-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- ODJQKYXPKWQWNK-UHFFFAOYSA-N 3,3'-Thiobispropanoic acid Chemical compound OC(=O)CCSCCC(O)=O ODJQKYXPKWQWNK-UHFFFAOYSA-N 0.000 description 1
- JAUFWPNLLLUYNV-UHFFFAOYSA-N 3-(16-methylheptadecoxy)propane-1,2-diol Chemical compound CC(C)CCCCCCCCCCCCCCCOCC(O)CO JAUFWPNLLLUYNV-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical compound O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 description 1
- AGNTUZCMJBTHOG-UHFFFAOYSA-N 3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]propane-1,2-diol Chemical compound OCC(O)COCC(O)COCC(O)CO AGNTUZCMJBTHOG-UHFFFAOYSA-N 0.000 description 1
- FVKRIDSRWFEQME-UHFFFAOYSA-N 3-methylbutyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCC(C)C FVKRIDSRWFEQME-UHFFFAOYSA-N 0.000 description 1
- GWXXFGWOWOJEEX-UHFFFAOYSA-N 4,4,4-trihydroxy-1-phenylbutan-1-one Chemical compound OC(CCC(=O)C1=CC=CC=C1)(O)O GWXXFGWOWOJEEX-UHFFFAOYSA-N 0.000 description 1
- JFMGYULNQJPJCY-UHFFFAOYSA-N 4-(hydroxymethyl)-1,3-dioxolan-2-one Chemical compound OCC1COC(=O)O1 JFMGYULNQJPJCY-UHFFFAOYSA-N 0.000 description 1
- RUEOYQNDBAHZBS-UHFFFAOYSA-N 4-[2-hydroxy-3-(2-hydroxy-3-octadecanoyloxypropoxy)propoxy]-4-oxobutanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COCC(O)COC(=O)CCC(O)=O RUEOYQNDBAHZBS-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 108010085443 Anserine Proteins 0.000 description 1
- XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- ONAIRGOTKJCYEY-XXDXYRHBSA-N CCCCCCCCCCCCCCCCCC(O)=O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ONAIRGOTKJCYEY-XXDXYRHBSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- XTJFFFGAUHQWII-UHFFFAOYSA-N Dibutyl adipate Chemical compound CCCCOC(=O)CCCCC(=O)OCCCC XTJFFFGAUHQWII-UHFFFAOYSA-N 0.000 description 1
- GHKOFFNLGXMVNJ-UHFFFAOYSA-N Didodecyl thiobispropanoate Chemical compound CCCCCCCCCCCCOC(=O)CCSCCC(=O)OCCCCCCCCCCCC GHKOFFNLGXMVNJ-UHFFFAOYSA-N 0.000 description 1
- 239000003508 Dilauryl thiodipropionate Substances 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000002656 Distearyl thiodipropionate Substances 0.000 description 1
- IUMSDRXLFWAGNT-UHFFFAOYSA-N Dodecamethylcyclohexasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 IUMSDRXLFWAGNT-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- WQXNXVUDBPYKBA-UHFFFAOYSA-N Ectoine Natural products CC1=NCCC(C(O)=O)N1 WQXNXVUDBPYKBA-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- HMEKVHWROSNWPD-UHFFFAOYSA-N Erioglaucine A Chemical compound [NH4+].[NH4+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 HMEKVHWROSNWPD-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical class C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- OQILCOQZDHPEAZ-UHFFFAOYSA-N Palmitinsaeure-octylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- ALQSHHUCVQOPAS-UHFFFAOYSA-N Pentane-1,5-diol Chemical class OCCCCCO ALQSHHUCVQOPAS-UHFFFAOYSA-N 0.000 description 1
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropanol Chemical compound CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000210053 Potentilla elegans Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010040904 Skin odour abnormal Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 239000003490 Thiodipropionic acid Substances 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000004904 UV filter Substances 0.000 description 1
- KGTSLTYUUFWZNW-PPJQWWMSSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate pyridine-4-carbohydrazide Chemical compound NNC(=O)c1ccncc1.CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C KGTSLTYUUFWZNW-PPJQWWMSSA-N 0.000 description 1
- RBAKOBGXSDZSNK-UHFFFAOYSA-N [3-bis[3-[dimethyl-[3-(octadecanoylamino)propyl]azaniumyl]-2-hydroxypropoxy]phosphoryloxy-2-hydroxypropyl]-dimethyl-[3-(octadecanoylamino)propyl]azanium trichloride Chemical compound [Cl-].[Cl-].[Cl-].CCCCCCCCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC(O)COP(=O)(OCC(O)C[N+](C)(C)CCCNC(=O)CCCCCCCCCCCCCCCCC)OCC(O)C[N+](C)(C)CCCNC(=O)CCCCCCCCCCCCCCCCC RBAKOBGXSDZSNK-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000011795 alpha-carotene Substances 0.000 description 1
- 235000003903 alpha-carotene Nutrition 0.000 description 1
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960001799 aurothioglucose Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 102000012265 beta-defensin Human genes 0.000 description 1
- 108050002883 beta-defensin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- BMRWNKZVCUKKSR-UHFFFAOYSA-N butane-1,2-diol Chemical compound CCC(O)CO BMRWNKZVCUKKSR-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940080421 coco glucoside Drugs 0.000 description 1
- 229940047648 cocoamphodiacetate Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000004064 cosurfactant Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
- 229940099500 cystamine Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 235000019304 dilauryl thiodipropionate Nutrition 0.000 description 1
- PKPOVTYZGGYDIJ-UHFFFAOYSA-N dioctyl carbonate Chemical compound CCCCCCCCOC(=O)OCCCCCCCC PKPOVTYZGGYDIJ-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- ZPRZNBBBOYYGJI-UHFFFAOYSA-L disodium;2-[1-[2-(carboxylatomethoxy)ethyl]-2-undecyl-4,5-dihydroimidazol-1-ium-1-yl]acetate;hydroxide Chemical compound [OH-].[Na+].[Na+].CCCCCCCCCCCC1=NCC[N+]1(CCOCC([O-])=O)CC([O-])=O ZPRZNBBBOYYGJI-UHFFFAOYSA-L 0.000 description 1
- 235000013804 distarch phosphate Nutrition 0.000 description 1
- 239000001245 distarch phosphate Substances 0.000 description 1
- PWWSSIYVTQUJQQ-UHFFFAOYSA-N distearyl thiodipropionate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCSCCC(=O)OCCCCCCCCCCCCCCCCCC PWWSSIYVTQUJQQ-UHFFFAOYSA-N 0.000 description 1
- 235000019305 distearyl thiodipropionate Nutrition 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- GJQLBGWSDGMZKM-UHFFFAOYSA-N ethylhexyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CC)CCCCC GJQLBGWSDGMZKM-UHFFFAOYSA-N 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940074046 glyceryl laurate Drugs 0.000 description 1
- 229940074050 glyceryl myristate Drugs 0.000 description 1
- 229940049294 glyceryl stearate se Drugs 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 210000004919 hair shaft Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- GSSQSKXMVHDFIQ-UHFFFAOYSA-N heptathionine Chemical compound S1SSSC=CSSS1 GSSQSKXMVHDFIQ-UHFFFAOYSA-N 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- ZUVCYFMOHFTGDM-UHFFFAOYSA-N hexadecyl dihydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(O)=O ZUVCYFMOHFTGDM-UHFFFAOYSA-N 0.000 description 1
- UFIYKNIUNRVRSI-UHFFFAOYSA-N hexadecyl octadecyl sulfate;sodium Chemical compound [Na].CCCCCCCCCCCCCCCCCCOS(=O)(=O)OCCCCCCCCCCCCCCCC UFIYKNIUNRVRSI-UHFFFAOYSA-N 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical class CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- AKCVDCXHMUUGRL-UHFFFAOYSA-N hexane-1,6-diol hexane-1,1,1-triol Chemical class OCCCCCCO.CCCCCC(O)(O)O AKCVDCXHMUUGRL-UHFFFAOYSA-N 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940078565 isoamyl laurate Drugs 0.000 description 1
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 125000005645 linoleyl group Chemical group 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 229960003035 magnesium gluconate Drugs 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940100573 methylpropanediol Drugs 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000011169 microbiological contamination Methods 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 150000002763 monocarboxylic acids Chemical class 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- ORPJZHOKKGOIGN-KNRYUCGFSA-N octadecanoic acid (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O ORPJZHOKKGOIGN-KNRYUCGFSA-N 0.000 description 1
- OEIJHBUUFURJLI-UHFFFAOYSA-N octane-1,8-diol Chemical compound OCCCCCCCCO OEIJHBUUFURJLI-UHFFFAOYSA-N 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229940086539 peg-7 glyceryl cocoate Drugs 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229950009195 phenylpropanol Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 229930195732 phytohormone Natural products 0.000 description 1
- 239000012165 plant wax Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- RMGVATURDVPNOZ-UHFFFAOYSA-M potassium;hexadecyl hydrogen phosphate Chemical compound [K+].CCCCCCCCCCCCCCCCOP(O)([O-])=O RMGVATURDVPNOZ-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
- DCBSHORRWZKAKO-UHFFFAOYSA-N rac-1-monomyristoylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(O)CO DCBSHORRWZKAKO-UHFFFAOYSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 125000005372 silanol group Chemical group 0.000 description 1
- 150000004819 silanols Chemical class 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229940096501 sodium cocoamphoacetate Drugs 0.000 description 1
- 229940057950 sodium laureth sulfate Drugs 0.000 description 1
- 229940045845 sodium myristate Drugs 0.000 description 1
- URLJMZWTXZTZRR-UHFFFAOYSA-N sodium myristyl sulfate Chemical compound CCCCCCCCCCCCCCOS(O)(=O)=O URLJMZWTXZTZRR-UHFFFAOYSA-N 0.000 description 1
- 229950005425 sodium myristyl sulfate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 1
- JUQGWKYSEXPRGL-UHFFFAOYSA-M sodium;tetradecanoate Chemical compound [Na+].CCCCCCCCCCCCCC([O-])=O JUQGWKYSEXPRGL-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000005555 sulfoximide group Chemical group 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 235000019303 thiodipropionic acid Nutrition 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 231100000186 toxicological potential Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 150000004072 triols Chemical class 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940040064 ubiquinol Drugs 0.000 description 1
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4933—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having sulfur as an exocyclic substituent, e.g. pyridinethione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
Definitions
- the present invention relates to the use of an agent for stimulating the gene expression of antimicrobial peptides (AMP).
- AMP antimicrobial peptides
- Antimicrobial preparations have long been known in pharmacy and cosmetics. They serve to eliminate a microbiological imbalance on body surfaces or in the oral cavity. Interfaces of the human organism (body) to the environment, in particular the skin with its appendages, such as the sweat or sebaceous glands, the gastrointestinal, the respiratory tract and the vaginal area are covered with numerous microorganisms, without disturbing the physiological balance. Rather, certain bacterial species are even necessary for health maintenance. Thus acidifying bacteria, e.g. Lactobacilli, by production of lactic acid lower the pH in the vagina and thus reduce the colonization with pathogenic germs.
- biocides intervene in the cell metabolism of bacteria and prevent their colonization or reduce microbiological contamination.
- biocides are usually exogenous substances which have a certain toxicological potential, in particular biocides Sensitizing properties are known, which have led even in younger representatives of this group of substances to a ban or a use restriction in cosmetic products.
- lipophilic alcohols are suitable as biocides, wherein, for example, DE 10 2010 027 947 A1 describes cyclohexanol as active ingredient in antiperspirants and deodorants.
- Caprylyl glycol in admixture with other biocides have been disclosed as a preservative system in DE 601 19 669 T2. Also elemental silver or silver ions have already been described as an active ingredient against microbiological body odor in cosmetic products.
- One of these disclosures is called, for example, DE 10 2009 027 604 AI.
- Probiotic active principles have also been proposed as antimicrobial protection, for example in skin treatment compositions, as disclosed in DE 10 2004 032 734 A1, or for the treatment of the gastrointestinal tract (disclosed in EP 2 277 524 A1 or GB 2 382 528 A).
- An antimicrobial peptide is a high-molecular-weight protein that only gets its effect through a certain steric spatial organization. It may therefore be doubted that it is possible to obtain particularly complex protein structures over the entire production route from the production or recovery of the protein to the finished cosmetic or pharmaceutical agent and to keep them stable over the entire storage life of the product.
- the invention is therefore based on the object to provide an agent which has good compatibility and stability and stimulates the body's synthesis of antimicrobial peptides.
- the agent contains a purine or a purine alkaloid, the latter selected from the group consisting of xanthine, theobromine, paraxanthin, theophylline, 3-isobutyl-1-methylxanthine (IBMX) and 1-methylxanthine.
- a purine or a purine alkaloid the latter selected from the group consisting of xanthine, theobromine, paraxanthin, theophylline, 3-isobutyl-1-methylxanthine (IBMX) and 1-methylxanthine.
- antimicrobial peptide stimulating agent AMP
- AMP antimicrobial peptide stimulating agent
- Dermcidin is a so-called antimicrobial peptide, which is synthesized in large quantities in the sweat glands and has only been detected there exclusively. It protects the epithelia by activating the immune system, in particular the chemokines and cytokines, and thus from microbiological attacks from the outside.
- the stimulation of an endogenous antimicrobial protective system may be called an ideal mode of action, which does not have the disadvantages described above; because the activation of the antimicrobial principle of action takes place via the body's own metabolic control circuits of humans.
- High gene induction represents the first step in a metabolic cascade that eventually leads to increased synthesis of the encoded peptide dermcidin in epithelial cells.
- the intrinsic stimulation is neither linked to the typical disadvantages of lack of compatibility nor to insufficient bioavailability, since the trigger purine or purine alkaloid for the release of dercidin has a particularly pronounced bioavailability.
- the intrinsic stimulation of dermcine synthesis via gene activation maintains the regulatory processes that prevent overdosage and thus undesired reactions. In particular, immune reactions to exogenous peptides are avoided, which can occur in topical, inhalative or oral dermidine or AMP application.
- DCD-1L kill pathogenic microorganisms such as Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, Staphylococcus epidermidis, Methicillin-resistant S. aureus, Rifampin and Isoniazid-resistant Mycobacterium tuberculosis, Pseudomonas putida, Listeria mono cytogen genes, Salmonella thyphimurium, and Candida albicans can.
- pathogenic microorganisms such as Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, Staphylococcus epidermidis, Methicillin-resistant S. aureus, Rifampin and Isoniazid-resistant Mycobacterium tuberculosis, Pseudomonas putida, Listeria mono cytogen genes, Salmonella thyphimurium, and Candida albicans can.
- the use of the agent can be enteral, intragastric, inhalative, intranasal, vaginal, (per) cutaneous or topical.
- the agent is a cosmetic agent.
- a hair treatment agent in particular rinses, cures, care creams, cleansers, hair tonics, scalp solutions, shampoos, fortifiers, gels, foams or in the form of a skin treatment agent, especially skin creams, masks, packs, wash emulsions, wash gels, aqueous alcoholic tonic solutions, serums, skin gels, lotions, fluids, deodorants or Antiperspirant or in the form of a treatment agent for the oral cavity, especially mouthwashes and ointments.
- the agent is a pharmaceutical agent.
- the agent is added to a pharmaceutical product or drug.
- a further embodiment of the invention provides that the agent contains caffeine.
- agent biocidal active substances selected from the group consisting of zinc compounds, in particular zinc pyrithione, zinc ricinoleates, zinc PCA or inorganic zinc salts, organohalogen compounds, in particular 2,4,4'-trichloro 2'-hydroxydiphenyl ether (Irgasan), l, 6-di- (4-chlorophenylbiguanido) hexane (chlorhexidine), 3,4,4'-trichlorocarbanilide, polyalcohols, especially clove oil, mint oil, thyme oil, triethyl citrate, farnesol (3,7 1 l-trimethyl-2,6,10-dodecatrien-1-ol).
- organohalogen compounds in particular 2,4,4'-trichloro 2'-hydroxydiphenyl ether (Irgasan), l, 6-di- (4-chlorophenylbiguanido) hexane (chlorhexidine), 3,4,4'-trichlor
- the agent contains anti-inflammatory agents, in particular selected from the group consisting of bisabolol, panthenol and tocopherol.
- the agent contains plant extracts, in particular selected from the group consisting of Echinacea, Ferula, Calendula and Melaleuca.
- purine and / or purine alkaloid is present as a derivative.
- the purine and / or purine alkaloid in a concentration of 0.001 to 10,000 parts by weight, preferably in a concentration of 0.01 to 5.00 parts by weight, most preferably in a concentration of 0.1 to 2.0 wt.
- Purines and / or purine alkaloids may be formulated together with other active ingredients and / or solvents, surfactants, emollients, vegetable, animal or synthetic lipids, fats or oils.
- the agent according to the invention contains gel formers on an inorganic or organic basis.
- Buffer systems with organic or inorganic acids keep the desired pH stable, preferably in the physiologically preferred range of 5-6.
- the agent contains active substances from the group of vitamins and vitamin derivatives, light protection filters, trace elements and / or plant extracts with biologically active phytoflavones, phytohormones and / or radical scavengers.
- antioxidants are used to stabilize purines and / or purine alkaloids and / or other active ingredients in the long term.
- Preferred active compounds from the aforementioned fields are humectants, in particular selected from the water-soluble polyhydric low to medium-chain alkanols (C2 to C6) with multiple hydroxyl groups and / or the water-soluble polyether compounds, straight-chain or branched-chain of glycols or diols or triols or polyols 3-20 monomer units and mixtures thereof.
- humectants in particular selected from the water-soluble polyhydric low to medium-chain alkanols (C2 to C6) with multiple hydroxyl groups and / or the water-soluble polyether compounds, straight-chain or branched-chain of glycols or diols or triols or polyols 3-20 monomer units and mixtures thereof.
- Preferred monomers are 1,2-propylene glycol, 2-methyl-1,3-propanediol, glycerol, butylene glycols such as 1,2-butylene glycol, 1,3-butylene glycol and 1,4-butylene glycol, pentylene glycols, hexanediols such as 1,6-hexanediol Hexane triols such as 1,2,6-hexanetriol, 1,8-octanediol, dipropylene glycol, tripropylene glycol, diglycerol, triglycerol, erythritol, sorbitol, inositol or xylitol and mixtures of the aforementioned substances.
- Sugar and certain sugar derivatives such as fructose, glucose, maltose, maltitol, mannitol, inositol, sucrose, trehalose, xylose, rhamnose and fucose can also be added to the composition according to the invention.
- the proposed sugar derivatives also include mono- or dicarboxylic acids of hexoses or pentoses. Likewise, amino acids, either individually or as a mixture, can be formulated as moisturizers.
- humectants are taurine, allantoin, (2-hydroxyethyl) urea, biosaccharides gum-1 and glycosaminoglycans and their salts and / or esters, especially hyaluronic acid, its salts and its silanol derivatives.
- the agent of the invention cooperates with one or more humectants.
- the humectant here is in a concentration of 0.01 to 35.00 parts by weight, preferably 1.0 to 15.0 parts by weight, most preferably in a concentration of 5.0 to 10.0 parts by weight, based on the overall recipe, before.
- agent may contain are selected from oligomers and polymers of amino acids as well as natural betaine compounds.
- Physiological active ingredients include vitamins, provitamins and vitamin precursors of groups A, B, C, E, H and K and their derivatives, alpha-hydroxycarboxylic acids, alpha-ketocarboxylic acids, beta-hydroxycarboxylic acids and their ester, lactone or salt form, flavonoids and flavonoid-rich plant extracts, isoflavonoids and isoflavonoid-rich plant extracts, polyphenols and polyphenol-rich plant extracts, ubiquinone and ubiquinol and their derivatives, ectoine, inorganic and organic UV filter substances, self-tanning active ingredients and skin-lightening active ingredients, and oligopeptides with alkyl or silanol side chains.
- the agent comprises a mixture of a plurality of oligopeptides.
- the agent poly- or oligopetides of N-acylamino acids having chain lengths of 2-26 carbon atoms.
- Starting peptides are derived either from animal sources, in particular elastin, collagen, keratin, silk and milk protein protein hydrolysates or from preferably plant sources, such as the plant family of legumes, grasses or cereals, the kernels of apricots or almonds.
- the agent also contains formulations with surface-active properties.
- protein hydrolysates and their acyl derivatives which may be present in the form of fatty acid condensation products or cationic protein hydrolysates, quaternary amino acids, oligopeptides, lipopeptides or acylated amino acids or peptides.
- Cocodimonium Hydroxypropyl Hydrolyzed Collagen Steardimonium Hydroxypropyl Hydrolyzed Collagen, Cocodimonium Hydroxypropyl Hydrolyzed Rice Protein, Cocodimonium Hydroxypropyl Hydrolyzed Silk, Cocodimonium Hydroxypropyl Hydrolyzed Soy Protein, Cocodimonium Hydroxypropyl Hydrolyzed Wheat Protein, Cocodimonium Hydroxypropyl Silk Amino Acids, Hydroxypropyl Arginine Lauryl / Myristyl Ether HCl (substance names are taken from the European Inventory of Cosmetic Ingredients, (COSING)).
- compositions are particularly suitable as additives to the composition.
- substances that bind to keratinic materials i.
- the horny layer of the skin or the cuticle of the hair shaft attach and improve their physical and sensory properties used.
- the agent may contain conditioning agents. This is beneficial because the conditioners smooth the surfaces of the skin and hair, repairing damaged areas and keeping them soft and supple.
- preferred conditioning agents are selected from fatty substances, especially vegetable oils, such as sunflower oil, olive oil, soybean oil, rapeseed oil, almond oil, jojoba oil, orange oil, wheat germ oil, peach kernel oil and the liquid portions of coconut oil, lanolin and its derivatives, liquid paraffin oils, isoparaffin oils and synthetic hydrocarbons, di-n-alkyl ethers having a total of 12 to 36 carbon atoms, for example di-n-octyl ether and n-hexyl n-octyl ether, fatty acids, in particular linear and / or branched, saturated and / or unsaturated C8-30 Fatty acids, fatty alcohols, in particular saturated, mono- or polyunsaturated, branched or unbranched fatty alcohols having 4-30 carbon atoms, ethoxylated with 1-75, preferably 5-20 ethylene oxide units and / or with 3-30, preferably 9-14 Propylene oxide units are propoxylated, ester oils,
- the invention provides that the components added to the agent are quaternized.
- the amount used for the Emolientien and / or care agents added to the agent in this case in a concentration of 0.1 to 50.0 wt.%, Preferably in a concentration from 0.1 to 20.0% by weight and most preferably in a concentration of 0.1-15.0% by weight, based in each case on the formulation.
- conditioning agents included in the composition of the invention may be unstable in the presence of oxygen. Therefore, the invention provides that they are stabilized with antioxidants.
- the antioxidants are selected from the group consisting of the amino acids (eg, glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg, urocanic acid) and their derivatives, DL-carnosine, D-carnosine, L Carnosine and its derivatives (eg anserine), carotenoids, carotenes (eg alpha-carotene, beta-carotene, lycopene) and their derivatives, chlorogenic acid and its derivatives, lipoic acid and its derivatives (eg dihydrolipoic acid), aurothioglucose, propylthiouracil and other thiols ( For example, thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, o
- alpha-hydroxy fatty acids phytic acid, glycosylrutin, ferulic acid, furfurylidene glucitol, butylhydroxytoluene, butylhydroxyanisole, nordihydroguajacic acid, nordihydroguajaret Textre, trihydroxybutyrophenone).
- Cleaning products for the skin or hair are preferably composed of a combination of anionic surfactants, amphoteric, nonionic, more rarely cationic surfactants, for example fatty alcohols of chain length C10 to C16, which are esterified with inorganic acids such as phosphoric acid, sulfuric acid or acetic acid.
- anionic surfactants amphoteric, nonionic, more rarely cationic surfactants
- fatty alcohols of chain length C10 to C16 which are esterified with inorganic acids such as phosphoric acid, sulfuric acid or acetic acid.
- inorganic acids such as phosphoric acid, sulfuric acid or acetic acid.
- These fatty acid esters are modified with polyethers.
- Suitable anionic surfactants are, for example, lauryl ether sulfate, lauryl sulfate, myristyl sulfate, laureth sulfosuccinates, ether carboxylates with a variable degree of ethoxylation, ether sulfonates based on amino acids, sugars and fatty alcohols.
- amphoteric cosurfactants such as cocamidopropyl betaine, cocoamphodiacetate, furthermore decyl polyglycosides, dodecyl polyglycosides, trilaureth 4-phosphates, di / mono sodium cocoamphoacetate, acyl / dialkylethylenediamine, for example, sodium acylampho acetate, disodium acyl amphodipropionate, disodium alkyl amphodiacetate, Sodium acylamphohydroxypropylsulfonate, disodium acylamphodiacetate and sodium acyl amphopropionate, N-alkylamino acids such as aminopropylalkylglutamide, alkylamino-propionic acid, sodium alkylimidodipropionate and lauroamphocarboxyglycinate.
- amphoteric cosurfactants such as cocamidopropyl betaine, cocoamphodiacetate, furthermore decyl polyg
- the anionic surfactants are preferably used in salt form.
- Suitable cations are alkali metal and alkaline earth metal ions, in particular sodium, potassium and magnesium.
- Nonionic surfactants are, for example, sarcosinates, e.g. Myristoyl sarcosinates, TEA lauroyl sarcosinates, Na lauroyl sarcosinates, Na cocoyl sarcosinates, fatty acid having a chain length of C10 to C20, saturated or unsaturated, acyl lysinates, alaninates or glycinates or fatty alcohol polyethers having 10 to 20 ethylene oxide or propylene oxide units.
- sarcosinates e.g. Myristoyl sarcosinates, TEA lauroyl sarcosinates, Na lauroyl sarcosinates, Na cocoyl sarcosinates, fatty acid having a chain length of C10 to C20, saturated or unsaturated, acyl lysinates, alaninates or glycinates or fatty alcohol polyethers having 10
- Cationic surfactants are primarily the already described as conditioning components quaternized N compounds from the group of amino acids, amino sugars or peptides.
- gel formers are contained in the means for optimizing the flow behavior.
- Gelling agents are, for example, organic thickeners, such as gum arabic, xanthan gum, sodium alginate, starch and starch derivatives (eg distarch phosphate), cellulose, cellulose derivatives, preferably methyl cellulose, Hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose,
- organic thickeners such as gum arabic, xanthan gum, sodium alginate, starch and starch derivatives (eg distarch phosphate), cellulose, cellulose derivatives, preferably methyl cellulose, Hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose,
- Hydroxypropylmethylcellulose or inorganic thickening agents such as aluminum silicates, such as organically modified or unmodified hectorites, bentonites, or the like, or a mixture of polyethylene glycol and polyethylene glycol stearate or distearate.
- aluminum silicates such as organically modified or unmodified hectorites, bentonites, or the like
- a mixture of polyethylene glycol and polyethylene glycol stearate or distearate such as a mixture of polyethylene glycol and polyethylene glycol stearate or distearate.
- biopolymers such as chitin or chitin derivatives or poly-glucuronic or polygalacturonic acids and their amides are suitable.
- Another group of particularly effective gels consists of modified polymers of acrylic acid.
- the thickener is contained in the gel in a concentration of 0.1 to 30.0 parts by weight, preferably in a concentration of 0.5 to 15.0 parts by weight.
- Prescriptions for the skin and hair care mainly consist of oils and care substances, which have to be stabilized in aqueous systems by means of emulsifiers.
- the invention provides that the agent contains emulsifiers.
- Suitable emulsifiers are, for example, PEG-n hydrogenated castor oil, PEG-n caprylic acid / capric acid glycerides, glyceryl oleate mixed with propylene glycol, PEG-n-stearate, ceteth-n, ceteth-n, polysorbate n, glyceryl stearate in admixture with PEG-n, glyceryl myristate, Glyceryl laurate, PEG-n-sorbitan peroleate, laureth-n, ceteareth-n, isostearyl glyceryl ether, cetylstearyl alcohol in admixture with sodium cetyl stearyl sulfate, lameth-n, steareth-n, glyceryl stearate in admixture with PEG-n stearate.
- PEG-n-stearate glycol distearate, PEG-n-dodecyl glycol, polyglyceryl-n-PEG-n-stearate, ceteareth-n, methyl glucose sesquistearate, steareth-n, PEG-n-stearate, steareth-n in admixture with PEG-n Distearate, steareth-n, steareth-n, isosteareth-n, PEG-n dodecyglycol copolymer, methoxy-PEG-n dodecyl glycol copolymer, PEG-n sorbitan peroleate, PEG-n sorbitan perisostearate, PEG-n-glyceryl stearate, PEG- n-glyceryl stearate, PEG-n beeswax, polyglyceryl n-laurate, isostearyl diglyceryl succinate, stearamidoprop
- the agent according to the invention can be best distributed on the surface of skin or hair, gastrointestinal or respiratory tract or vaginal area with the abovementioned active ingredient combinations, a specific galenic formulation is necessary. This depends on the individual needs of the user.
- the agent according to the invention for dermatological applications in the form of a liquid, flowable or solid oil-in-water emulsion, water-in-oil emulsion, multiple emulsion, in particular an oil-in-water-in-oil or water-in-oil-in-water emulsion, macroemulsion, microemulsion, PIT emulsion, nanoemulsion, hydrodispersion, hydrogel, lipogel, mono- or multiphase solution, foam, aqueous-alcoholic solution or surfactant formulation is present.
- the agent with applicators such as dosing tips or spray dosing in the form of aqueous, aqueous-alcoholic solutions, lotions or gels is administered.
- agent according to the invention is used for sprays, roll-ons and deodorants.
- alcoholic lotions, hair creams or scalp waters for example, soaps, cleansing gels, cleansing gels, shampoos, foams, cleansing sprays, rinses, cures, alcoholic lotions, hair creams or scalp waters are provided.
- soaps, cleansing gels, cleansing gels, shampoos, foams, cleansing sprays, rinses, cures, alcoholic lotions, hair creams or scalp waters are provided.
- the following formulation examples are intended to illustrate the subject matter of the invention without limiting it thereto. All data are in parts by weight based on the total composition. The substance names are taken from the binding inventory of cosmetic ingredients, COSING.
- Anti-dandruff shampoo (in% by weight)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The object of the invention is to provide an agent which has good acceptability and stability and also gives rise to an antimicrobial effect. This object is achieved according to the invention in that the agent contains a purine or a purine alkaloid, the latter selected from the group consisting of xanthine, theobromine, paraxanthine, theophylline, 3-isobutyl-1-methylxanthine (IBMX) and 1-methylxanthine.
Description
BESCHREIBUNG DESCRIPTION
Verwendung eines Mittels zur Stimulation der Gen-Expression antimikrobieller Peptide Use of an agent for stimulating gene expression of antimicrobial peptides
(AMP) (AMP)
Die vorliegende Erfindung betrifft die Verwendung eines Mittels zur Stimulation der Gen- Expression antimikrobieller Peptide (AMP). The present invention relates to the use of an agent for stimulating the gene expression of antimicrobial peptides (AMP).
Antimikrobielle Zubereitungen sind in der Pharmazie und Kosmetik schon lange bekannt. Sie dienen dazu, ein mikrobiologisches Ungleichgewicht auf Körperoberflächen oder in der Mundhöhle zu beseitigen. Grenzflächen des menschlichen Organismus (Körper) zur Umwelt, insbesondere die Haut mit ihren Anhangsgebilden, wie beispielsweise den Schweiß- oder Talgdrüsen, der Gastrointestinal-, der Respirationstrakt und der Vaginalbereich sind mit zahlreichen Mikroorganismen bedeckt, ohne dass es zu Störungen des physiologischen Gleichgewichtes kommt. Vielmehr sind bestimmte Bakterien-Spezies sogar für die Gesundhaltung notwendig. So können säurebildende Bakterien, z.B. Lactobazillen, durch Produktion von Milchsäure den pH- Wert in der Scheide absenken und so die Besiedelung mit pathogenen Keimen verringern. Antimicrobial preparations have long been known in pharmacy and cosmetics. They serve to eliminate a microbiological imbalance on body surfaces or in the oral cavity. Interfaces of the human organism (body) to the environment, in particular the skin with its appendages, such as the sweat or sebaceous glands, the gastrointestinal, the respiratory tract and the vaginal area are covered with numerous microorganisms, without disturbing the physiological balance. Rather, certain bacterial species are even necessary for health maintenance. Thus acidifying bacteria, e.g. Lactobacilli, by production of lactic acid lower the pH in the vagina and thus reduce the colonization with pathogenic germs.
An bestimmten Körperflächen können durch Mikroorganismen und die dort vorhandenen Enzyme Hautlipide und andere Stoffe gespalten und metabolisiert werden. Die Folge sind lokale Hautreizungen (durch Freisetzung von Fettsäuren) oder unangenehme Körpergerüche. Auch die Bildung seborrhoischer Schuppen ist das Resultat mikrobiologischer Stoffwechselprodukte. Hieraus folgen lokale Reizungen der Kopf- oder Gesichtshaut mit anschließender Hyperproliferation der Keratinozyten in der Epidermis. On certain body surfaces, skin lipids and other substances can be split and metabolized by microorganisms and the enzymes present there. The result is local skin irritation (due to the release of fatty acids) or unpleasant body odors. The formation of seborrheic scales is also the result of microbiological metabolites. This is followed by local irritation of the scalp or facial skin followed by hyperproliferation of the keratinocytes in the epidermis.
Bisher war es üblich, synthetische oder natürliche biozide Stoffe gegen solche Mikroorganismen durch äußerliche Anwendung einzusetzen. Diese Biozide greifen in den Zellstoffwechsel von Bakterien ein und verhindern deren Besiedelung bzw. verringern mikrobiologische Kontaminationen. Solche Biozide sind in der Regel körperfremde Stoffe, die ein gewisses toxikologisches Potential besitzen, insbesondere sind bei Bioziden
sensibilisierende Eigenschaften bekannt, die sogar bei jüngeren Vertretern dieser Stoffgruppe zu einem Verbot oder einer Einsatzbeschränkung in kosmetischen Mitteln geführt haben. Lipophile Alkohole sind als Biozide geeignet, wobei beispielsweise in der DE 10 2010 027 947 AI Cyclohexanol als Wirkstoff in Antitranspirantien und Deodorants beschrieben wurde. Caprylylglycol in Mischung mit anderen Bioziden wurden als Konservierungssystem in der DE 601 19 669 T2 offenbart. Auch elementares Silber oder Silberionen wurden bereits als Wirkstoff gegen mikrobiologisch bedingten Körpergeruch in kosmetischen Mitteln beschrieben. Eine dieser Offenbarungen ist beispielsweise die DE 10 2009 027 604 AI genannt. So far, it has been customary to use synthetic or natural biocidal substances against such microorganisms by external application. These biocides intervene in the cell metabolism of bacteria and prevent their colonization or reduce microbiological contamination. Such biocides are usually exogenous substances which have a certain toxicological potential, in particular biocides Sensitizing properties are known, which have led even in younger representatives of this group of substances to a ban or a use restriction in cosmetic products. Lipophilic alcohols are suitable as biocides, wherein, for example, DE 10 2010 027 947 A1 describes cyclohexanol as active ingredient in antiperspirants and deodorants. Caprylyl glycol in admixture with other biocides have been disclosed as a preservative system in DE 601 19 669 T2. Also elemental silver or silver ions have already been described as an active ingredient against microbiological body odor in cosmetic products. One of these disclosures is called, for example, DE 10 2009 027 604 AI.
Nachteilig für die beiden letztgenannten Stoffe ist jedoch, dass sie körperfremd sind und daher auch möglicherweise Risiken in der Anwendung aufweisen. However, a disadvantage of the latter two substances is that they are foreign to the body and therefore may also present risks in use.
Auch probiotische Wirkprinzipien wurden als antimikrobieller Schutz beispielsweise in Hautbehandlungsmitteln, wie in der DE 10 2004 032 734 AI offenbart, oder zur Behandlung des Gastrointestinaltraktes (offenbart in der EP 2 277 524 AI oder GB 2 382 528 A) vorgeschlagen. Probiotic active principles have also been proposed as antimicrobial protection, for example in skin treatment compositions, as disclosed in DE 10 2004 032 734 A1, or for the treatment of the gastrointestinal tract (disclosed in EP 2 277 524 A1 or GB 2 382 528 A).
Ein ganz anderer Ansatz wurde in der DE 10 2005 014 687 AI vorgestellt. Dort wird ein Zusatz von ß-Defensin, einem antimikrobiellen Peptid (AMP), in kosmetischen Mitteln beschrieben. A completely different approach was presented in DE 10 2005 014 687 AI. There is described an addition of β-defensin, an antimicrobial peptide (AMP), in cosmetic products.
Ein antimikrobielles Peptid ist ein hochmolekulares Protein, das seine Wirkung erst durch eine bestimmte sterische Raumordnung erhält. Es darf daher bezweifelt werden, dass es gelingt, besonders komplexe Proteinstrukturen über den gesamten Produktionsweg von der Herstellung bzw. Gewinnung des Proteins bis zum fertigen kosmetischen oder pharmazeutischen Mittel zu erhalten und diese über die gesamte Lagerzeit des Produktes stabil zu halten. An antimicrobial peptide is a high-molecular-weight protein that only gets its effect through a certain steric spatial organization. It may therefore be doubted that it is possible to obtain particularly complex protein structures over the entire production route from the production or recovery of the protein to the finished cosmetic or pharmaceutical agent and to keep them stable over the entire storage life of the product.
Somit gibt es bisher keine zufriedenstellende Lösung eines bioziden Wirkprinzips in pharmazeutischen und kosmetischen Produkten, das gleichermaßen die Anforderungen an die Wirkung und die Verträglichkeit erfüllt.
Der Erfindung liegt daher die Aufgabe zugrunde, ein Mittel bereitzustellen, das eine gute Verträglichkeit und Stabilität aufweist sowie die körpereigene Synthese antimikrobieller Peptide stimuliert. Thus, there is so far no satisfactory solution of a biocidal active principle in pharmaceutical and cosmetic products, which meets both the requirements for the effect and the compatibility. The invention is therefore based on the object to provide an agent which has good compatibility and stability and stimulates the body's synthesis of antimicrobial peptides.
Diese Aufgabe wird erfindungsgemäß dadurch gelöst, dass das Mittel ein Purin oder ein Purinalkaloid, letzteres ausgewählt aus der Gruppe bestehend aus Xanthin, Theobromin, Paraxanthin, Theophyllin, 3-Isobutyl-l-methylxanthin (IBMX) und 1-Methylxanthin enthält. This object is achieved according to the invention in that the agent contains a purine or a purine alkaloid, the latter selected from the group consisting of xanthine, theobromine, paraxanthin, theophylline, 3-isobutyl-1-methylxanthine (IBMX) and 1-methylxanthine.
Es ist weiterhin vorgesehen, dass die Verwendung des Mittels zur Stimulation der Synthese antimikrobieller Peptide (AMP) insbesondere die Synthese des antimikrobiellen Peptids Dermcidin steigert. It is further envisaged that the use of the antimicrobial peptide stimulating agent (AMP) will in particular enhance the synthesis of the antimicrobial peptide dermcidin.
Dermcidin ist ein sogenanntes antimikrobielles Peptid, das in großer Menge in den Schweißdrüsen synthetisiert wird und auch nur dort bisher ausschließlich nachgewiesen worden ist. Es schützt die Epithelien durch Aktivierung des Immunsystems insbesondere der Chemokine und Cytokine und damit vor mikrobiologischen Angriffen von außen. Dermcidin is a so-called antimicrobial peptide, which is synthesized in large quantities in the sweat glands and has only been detected there exclusively. It protects the epithelia by activating the immune system, in particular the chemokines and cytokines, and thus from microbiological attacks from the outside.
Die Stimulation eines körpereigenen antimikrobiellen Schutzsystem darf als ideales Wirkprinzip bezeichnet werden, das nicht die oben beschriebenen Nachteile aufweist; denn die Aktivierung des antimikrobiellen Wirkprinzips erfolgt über die körpereigenen, metabolischen Regelkreise des Menschen. The stimulation of an endogenous antimicrobial protective system may be called an ideal mode of action, which does not have the disadvantages described above; because the activation of the antimicrobial principle of action takes place via the body's own metabolic control circuits of humans.
Bei der Untersuchung des Wirkmechanismus von Purinen bzw. Purinalkaloiden mittels Genexpressionsstudien (Gen-Array) zur Stabilisierung des Haarwachstums wurde zur Überraschung der Erfinder gefunden, dass Purine und Purinalkaloide in Haarwurzeln eine signifikant erhöhte Expression des Gens für das antimikrobielle Peptid Dermcidin (DCD) zeigte, wobei dies ein Hinweis darauf ist, dass damit dessen Proteinsynthese initiiert wird. Die Hochregulierung des DCD-Gens war nach 120 Std. Inkubation mit beispielsweise Purinalkaloide bei humanen männlichen Haarwurzeln maximal 14.5-fach im Vergleich zu einer Kontrollgruppe, wobei nach 24 Std. Inkubation die Expression des DCD-Gens bei männlichen Haarfollikeln maximal 171-fach und bei weiblichen maximal 286-fach war. Mittels quantitativer real-time-PCR als bestätigende Untersuchung der im Gen-Array identifizierten Gene, konnte für 9 von 12 verschiedenen Individuen (beiderlei Geschlechts)
eine starke Hochregulation des DCD-Gens nach Purin bzw. Purinalkaloid-Behandlung bestätigt werden. In investigating the mechanism of action of purines or purine alkaloids by gene expression studies (gene array) to stabilize hair growth, it was surprisingly found by the inventor that purines and purine alkaloids in hair roots showed significantly increased expression of the antimicrobial peptide dermcidin (DCD) gene, this being an indication that this will initiate its protein synthesis. The upregulation of the DCD gene was after a 120 hr. Incubation with, for example Purinalkaloide in human male hair roots a maximum of 14.5-fold compared to a control group, wherein after 24 hr. Incubation, the expression of the DCD gene in male hair follicles a maximum of 171-fold and Female was a maximum of 286-fold. By means of quantitative real-time PCR as confirmatory examination of the genes identified in the gene array, it was possible for 9 out of 12 different individuals (both sexes) strong upregulation of the DCD gene after purine or purine alkaloid treatment can be confirmed.
Die hohe Gen-Induktion stellt den ersten Schritt einer metabolischen Kaskade dar, die schließlich zu einer verstärkten Synthese des codierten Peptids Dermcidin in Epithelzellen führt. Mit der intrinsischen Stimulation sind weder die typischen Nachteile mangelnder Verträglichkeit verknüpft, noch sind unzureichende biologische Verfügbarkeit zu erwarten, da der Trigger Purin bzw. Purinalkaloid für die Freisetzung von Dermcidin eine besonders ausgeprägte biologische Verfügbarkeit hat. Durch die intrinsische Stimulation der Dermcidin- Synthese via Genaktivierung bleiben die Regelprozesse erhalten, die eine Überdosierung und damit unerwünschte Reaktionen verhindern. Insbesondere werden auch Immunreaktionen gegen körperfremde Peptide vermieden, die bei topischer, inhalativer oder oraler Dermcidin bzw. AMP Anwendung auftreten können. High gene induction represents the first step in a metabolic cascade that eventually leads to increased synthesis of the encoded peptide dermcidin in epithelial cells. The intrinsic stimulation is neither linked to the typical disadvantages of lack of compatibility nor to insufficient bioavailability, since the trigger purine or purine alkaloid for the release of dercidin has a particularly pronounced bioavailability. The intrinsic stimulation of dermcine synthesis via gene activation maintains the regulatory processes that prevent overdosage and thus undesired reactions. In particular, immune reactions to exogenous peptides are avoided, which can occur in topical, inhalative or oral dermidine or AMP application.
Weiterhin ist es vorteilhaft, dass die Verwendung des Mittels zur Stimulation der Synthese des anionischen DCD-1L führt. Furthermore, it is advantageous that the use of the means for stimulating the synthesis of the anionic DCD-1L leads.
Es ist bekannt, dass DCD-1L pathogene Mikroorganismen wie Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, Staphylococcus epidermidis, Methicillinresistente S. aureus, Rifampin- und Isoniazidresistente Mycobacterium tuberculosis, Pseudomonas putida, Listeria mono cyto genes, Salmonella thyphimurium, und Candida albicans töten kann. It is known that DCD-1L kill pathogenic microorganisms such as Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, Staphylococcus epidermidis, Methicillin-resistant S. aureus, Rifampin and Isoniazid-resistant Mycobacterium tuberculosis, Pseudomonas putida, Listeria mono cytogen genes, Salmonella thyphimurium, and Candida albicans can.
Daher ist weiterhin vorgesehen, dass die Verwendung des Mittels enteral, intragastral, inhalativ, intranasal, vaginal, (per)kutan oder topisch erfolgen kann. Therefore, it is further envisaged that the use of the agent can be enteral, intragastric, inhalative, intranasal, vaginal, (per) cutaneous or topical.
Es ist ebenfalls zu der Erfindung gehörig, dass das Mittel ein kosmetisches Mittel ist. It is also part of the invention that the agent is a cosmetic agent.
Hierbei ist vorgesehen, dass das in Form eines Haarbehandlungsmittels, insbesondere Spülungen, Kuren, Pflegecremes, Reinigungsmittel, Haartonics, Kopfhautlösungen, Shampoos, Festiger, Gele, Schäume oder in Form eines Hautbehandlungsmittels, insbesondere Hautcremes, Masken, Packungen, Waschemulsionen, Waschgelen, wässrige alkoholische, tonische Lösungen, Seren, Hautgele, Lotionen, Fluids, Deo- oder
Antitranspiranzprodukte oder in Form eines Behandlungsmittels für die Mundhöhle, insbesondere Mundwässer und Salben vorliegt. It is provided that in the form of a hair treatment agent, in particular rinses, cures, care creams, cleansers, hair tonics, scalp solutions, shampoos, fortifiers, gels, foams or in the form of a skin treatment agent, especially skin creams, masks, packs, wash emulsions, wash gels, aqueous alcoholic tonic solutions, serums, skin gels, lotions, fluids, deodorants or Antiperspirant or in the form of a treatment agent for the oral cavity, especially mouthwashes and ointments.
Es ist weiterhin vorstellbar, dass das Mittel ein pharmazeutisches Mittel ist. Jedoch ist auch vorstellbar, dass das Mittel zu einem pharmazeutischen Produkt bzw. Medikament zugesetzt wird. It is further conceivable that the agent is a pharmaceutical agent. However, it is also conceivable that the agent is added to a pharmaceutical product or drug.
Eine weitere Ausgestaltung der Erfindung sieht vor, dass das Mittel Koffein enthält. A further embodiment of the invention provides that the agent contains caffeine.
Eine Weiterbildung der Erfindung sieht vor, dass das Mittel biozide Wirkstoffe, ausgewählt aus der Gruppe bestehend aus Zinkverbindungen, insbesondere Zink-Pyrithion, Zink- Ricinoleate, Zink-PCA oder anorganische Zinksalze, halogenorganischen Verbindungen, insbesondere 2,4,4'-Trichlor-2'-hydroxydiphenylether (Irgasan), l,6-Di-(4- chlorphenylbiguanido)-hexan (Chlorhexidin), 3,4,4'-Trichlorcarbanilid, Polyalkohole, insbesondere Nelkenöl, Minzöl, Thymianöl, Triethylcitrat, Farnesol (3,7,1 l-Trimethyl-2,6, 10- dodecatrien-I-ol) enthält. A development of the invention provides that the agent biocidal active substances selected from the group consisting of zinc compounds, in particular zinc pyrithione, zinc ricinoleates, zinc PCA or inorganic zinc salts, organohalogen compounds, in particular 2,4,4'-trichloro 2'-hydroxydiphenyl ether (Irgasan), l, 6-di- (4-chlorophenylbiguanido) hexane (chlorhexidine), 3,4,4'-trichlorocarbanilide, polyalcohols, especially clove oil, mint oil, thyme oil, triethyl citrate, farnesol (3,7 1 l-trimethyl-2,6,10-dodecatrien-1-ol).
Weiterhin ist es vorteilhaft, dass das Mittel antiinflammatorische Wirkstoffe, insbesondere ausgewählt aus der Gruppe bestehend aus Bisabolol, Panthenol und Tocopherol enthält. Furthermore, it is advantageous that the agent contains anti-inflammatory agents, in particular selected from the group consisting of bisabolol, panthenol and tocopherol.
Es ist zudem vorgesehen, dass das Mittel Pflanzenextrakte, insbesondere ausgewählt aus der Gruppe bestehend aus Echinacea, Ferula, Calendula und Melaleuca enthält. It is also envisaged that the agent contains plant extracts, in particular selected from the group consisting of Echinacea, Ferula, Calendula and Melaleuca.
Es ist ebenfalls zu der Erfindung gehörig, dass das Purin und/oder Purinalkaloid als Derivat vorliegt. It is also part of the invention that the purine and / or purine alkaloid is present as a derivative.
Für das erfindungsgemäße Mittel ist vorgesehen, dass das Purin und/oder Purinalkaloid in einer Konzentration von 0,001 bis 10,000 Gew.- , vorzugsweise in einer Konzentration von 0,01 bis 5,00 Gew.- , höchst vorzugsweise in einer Konzentration von 0,1 bis 2,0 Gew.- vorliegt.
Purine und/oder Purinalkaloide können zusammen mit weiteren Wirkstoffen und/oder Lösungsmitteln, Tensiden, Emollientien, pflanzlicher, tierischer oder synthetischer Lipide, Fette oder Öle formuliert werden. For the agent according to the invention it is provided that the purine and / or purine alkaloid in a concentration of 0.001 to 10,000 parts by weight, preferably in a concentration of 0.01 to 5.00 parts by weight, most preferably in a concentration of 0.1 to 2.0 wt. Purines and / or purine alkaloids may be formulated together with other active ingredients and / or solvents, surfactants, emollients, vegetable, animal or synthetic lipids, fats or oils.
Zur Stabilisierung der Konsistenz und des Fließverhaltens, ist weiterhin vorgesehen, dass das erfindungsgemäße Mittel Gelbildner auf anorganischer oder organischer Grundlage enthält. To stabilize the consistency and the flow behavior, it is further provided that the agent according to the invention contains gel formers on an inorganic or organic basis.
Puffersysteme mit organischen oder anorganischen Säuren halten den erwünschten pH- Wert möglichst im physiologisch bevorzugten Bereich von 5-6 stabil. Buffer systems with organic or inorganic acids keep the desired pH stable, preferably in the physiologically preferred range of 5-6.
Weiterhin ist vorteilhaft, dass das Mittel Wirkstoffe aus der Gruppe der Vitamine und Vitaminderivate, Lichtschutzfilter, Spurenelemente und/oder Pflanzenextrakte mit biologisch aktiven Phytoflavonen, Phytohormonen und/oder Radikalfängern enthält. Furthermore, it is advantageous that the agent contains active substances from the group of vitamins and vitamin derivatives, light protection filters, trace elements and / or plant extracts with biologically active phytoflavones, phytohormones and / or radical scavengers.
Es ist für das erfindungsgemäße Mittel weiterhin vorgesehen, dass Antioxidationsmittel eingesetzt werden um Purine und/oder Purinalkaloide und/oder andere Wirkstoffe langfristig zu stabilisieren. It is further envisaged for the agent according to the invention that antioxidants are used to stabilize purines and / or purine alkaloids and / or other active ingredients in the long term.
Bevorzugte Wirkstoffe aus den zuvor genannten Gebieten sind Feuchthaltemittel, insbesondere ausgewählt aus den wasserlöslichen mehrwertigen niedrig- bis mittelkettigen Alkanolen (C2 bis C6) mit mehrfachen Hydroxylgruppen und/oder den wasserlöslichen Polyetherverbindungen, geradkettig oder verzweigtkettig von Glycolen bzw. Diolen oder Trio- bzw Polyolen mit 3-20 Monomer-Einheiten sowie Mischungen hiervon. Bevorzugte Monomere sind 1,2-Propylenglycol, 2-Methyl-l,3-propandiol, Glycerin, Butylenglycolen wie 1,2-Butylenglycol, 1,3-Butylenglycol und 1,4-Butylenglycol, Pentylenglycolen, Hexandiolen wie 1,6-Hexandiol, Hexantriolen wie 1,2,6-Hexantriol, 1,8- Octandiol, Dipropylenglycol, Tripropylenglycol, Diglycerin, Triglycerin, Erythritol, Sorbitol, Inositol oder Xylitol sowie Mischungen der vorgenannten Substanzen. Preferred active compounds from the aforementioned fields are humectants, in particular selected from the water-soluble polyhydric low to medium-chain alkanols (C2 to C6) with multiple hydroxyl groups and / or the water-soluble polyether compounds, straight-chain or branched-chain of glycols or diols or triols or polyols 3-20 monomer units and mixtures thereof. Preferred monomers are 1,2-propylene glycol, 2-methyl-1,3-propanediol, glycerol, butylene glycols such as 1,2-butylene glycol, 1,3-butylene glycol and 1,4-butylene glycol, pentylene glycols, hexanediols such as 1,6-hexanediol Hexane triols such as 1,2,6-hexanetriol, 1,8-octanediol, dipropylene glycol, tripropylene glycol, diglycerol, triglycerol, erythritol, sorbitol, inositol or xylitol and mixtures of the aforementioned substances.
Geeignete wasserlösliche Polyethylenglycole sind ausgewählt aus PEG-n mit n = 2 bis 20 sowie Mischungen hiervon, wobei n = 3 bis 8 bevorzugt sind. Auch Zucker und bestimmte Zuckerderivate wie Fructose, Glucose, Maltose, Maltitol, Mannit, Inosit, Sucrose, Trehalose, Xylose, Rhamnose und Fucose können dem erfindungsgemäßen Mittel zugesetzt werden.
Die vorgeschlagenen Zuckerderivate schließen auch Mono- oder Dicarbonsäuren der Hexosen oder Pentosen ein. Ebenfalls Aminosäuren, entweder einzeln oder als Gemisch, können als Feuchthaltestoffe rezeptiert werden. Andere Feuchthaltemittel sind Taurin, Allantoin, (2- Hydroxyethyl)-harnstoff, Biosaccharide Gum-1 und Glycosaminoglycane und deren Salze und/oder Ester, insbesondere Hyaluronsäure, ihre Salze und ihre Silanolderivate. Suitable water-soluble polyethylene glycols are selected from PEG-n with n = 2 to 20 and mixtures thereof, where n = 3 to 8 are preferred. Sugar and certain sugar derivatives such as fructose, glucose, maltose, maltitol, mannitol, inositol, sucrose, trehalose, xylose, rhamnose and fucose can also be added to the composition according to the invention. The proposed sugar derivatives also include mono- or dicarboxylic acids of hexoses or pentoses. Likewise, amino acids, either individually or as a mixture, can be formulated as moisturizers. Other humectants are taurine, allantoin, (2-hydroxyethyl) urea, biosaccharides gum-1 and glycosaminoglycans and their salts and / or esters, especially hyaluronic acid, its salts and its silanol derivatives.
Es ist weiterhin vorgesehen, dass das erfindungsgemäße Mittel mit einem oder mehreren Feuchthaltemitteln zusammenwirkt. Das Feuchthaltemittel liegt hierbei in einer Konzentration von 0,01 bis 35,00 Gew.- , vorzugsweise 1,0 bis 15,0 Gew.- , höchst vorzugsweise in einer Konzentration von 5,0 bis 10,0 Gew.- , bezogen auf die Gesamtrezeptur, vor. It is further contemplated that the agent of the invention cooperates with one or more humectants. The humectant here is in a concentration of 0.01 to 35.00 parts by weight, preferably 1.0 to 15.0 parts by weight, most preferably in a concentration of 5.0 to 10.0 parts by weight, based on the overall recipe, before.
Weitere bevorzugte Wirkstoffe, die das Mittel enthalten kann, sind ausgewählt aus Oligomeren und Polymeren von Aminosäuren sowie natürlichen B etain Verbindungen. Other preferred agents which the agent may contain are selected from oligomers and polymers of amino acids as well as natural betaine compounds.
Physiologische Aktivstoffe sind unter anderem Vitamine, Provitamine und Vitaminvorstufen der Gruppen A, B, C, E, H und K und deren Derivate, alpha-Hydroxycarbonsäuren, alpha- Ketocarbonsäuren, beta-Hydroxycarbonsäuren und deren Ester-, Lacton- oder Salzform, Flavonoide und flavonoidreiche Pflanzenextrakten, Isoflavonoide und isoflavonoidreiche Pflanzenextrakten, Polyphenole und polyphenolreiche Pflanzenextrakten, Ubichinon und Ubichinol sowie deren Derivate, Ectoin, anorganische und organische UV-Filtersubstanzen, selbstbräunende Wirkstoffe sowie hautaufhellenden Wirkstoffe, sowie Oligopeptide mit Alkyl- oder Silanolseitenketten. Physiological active ingredients include vitamins, provitamins and vitamin precursors of groups A, B, C, E, H and K and their derivatives, alpha-hydroxycarboxylic acids, alpha-ketocarboxylic acids, beta-hydroxycarboxylic acids and their ester, lactone or salt form, flavonoids and flavonoid-rich plant extracts, isoflavonoids and isoflavonoid-rich plant extracts, polyphenols and polyphenol-rich plant extracts, ubiquinone and ubiquinol and their derivatives, ectoine, inorganic and organic UV filter substances, self-tanning active ingredients and skin-lightening active ingredients, and oligopeptides with alkyl or silanol side chains.
Weiterhin ist erfindungsgemäß vorgesehen, dass das Mittel ein Gemisch aus mehreren Oligopeptiden aufweist. Furthermore, the invention provides that the agent comprises a mixture of a plurality of oligopeptides.
Sofern es vonnöten ist, dass oben beschriebene Säuren neutralisiert werden müssen oder neutralisierte Säuren bzw. Salze eingesetzt werden, können Kationen der Ammonium-, Alkalimetall-, Aluminium-, Calcium-, Kupfer, Magnesium-, Mangan-Salzen und Zink-, bevorzugt die Aluminium-, Kalium-, Magnesium-, Natrium-, Mangan- und Zink-Salze dem Mittel zugefügt werden.
Weiterhin ist erfindungsgemäß vorgesehen, dass das Mittel Poly- oder Oligopetide der N- Acylamino säuren mit Kettenlängen von 2-26 Kohlenstoffatomen enthält. If it is necessary that the above-described acids must be neutralized or neutralized acids or salts are used, cations of ammonium, alkali metal, aluminum, calcium, copper, magnesium, manganese salts and zinc, preferably the Aluminum, potassium, magnesium, sodium, manganese and zinc salts are added to the agent. Furthermore, the invention provides that the agent poly- or oligopetides of N-acylamino acids having chain lengths of 2-26 carbon atoms.
Diese können sowohl durch Synthese von Einzelkomponenten als auch durch Hydrolyse komplexer Peptide gewonnen werden. Ausgangspeptide stammen entweder aus tierischen Quellen, insbesondere Elastin-, Collagen-, Keratin-, Seiden- und Milcheiweiß- Proteinhydrolysate oder aus bevorzugt pflanzlichen Quellen, wie beispielsweise der Pflanzenfamilie der Hülsenfrüchtler, der Gräser bzw. Getreide, der Kerne von Aprikosen oder Mandeln. These can be obtained both by synthesis of individual components and by hydrolysis of complex peptides. Starting peptides are derived either from animal sources, in particular elastin, collagen, keratin, silk and milk protein protein hydrolysates or from preferably plant sources, such as the plant family of legumes, grasses or cereals, the kernels of apricots or almonds.
Es ist zu der Erfindung gehörig, dass das Mittel auch Formulierungen mit oberflächenaktiven Eigenschaften enthält. It is part of the invention that the agent also contains formulations with surface-active properties.
Hierbei ist der Einsatz von Proteinhydrolysaten und ihrer Acylderivate vorgesehen, wobei diese in Form von Fettsäure-Kondensationsprodukten oder kationischen Proteinhydrolysaten, quaternären Aminosäuren, Oligopeptiden, Lipopeptide bzw. acylierte Aminosäuren bzw. Peptide vorliegen können. Here, the use of protein hydrolysates and their acyl derivatives is provided, which may be present in the form of fatty acid condensation products or cationic protein hydrolysates, quaternary amino acids, oligopeptides, lipopeptides or acylated amino acids or peptides.
Beispielhaft für diese sind Cocodimonium Hydroxypropyl Hydrolyzed Collagen, Steardimonium Hydroxypropyl Hydrolyzed Collagen, Cocodimonium Hydroxypropyl Hydrolyzed Rice Protein, Cocodimonium Hydroxypropyl Hydrolyzed Silk, Cocodimonium Hydroxypropyl Hydrolyzed Soy Protein, Cocodimonium Hydroxypropyl Hydrolyzed Wheat Protein, Cocodimonium Hydroxypropyl Silk Amino Acids, Hydroxypropyl Arginine Lauryl/Myristyl Ether HCl genannt (die Stoffbezeichnungen sind dem europäischen Inventar kosmetischer Inhalts Stoffe, (COSING) entnommen). Exemplary of these are Cocodimonium Hydroxypropyl Hydrolyzed Collagen, Steardimonium Hydroxypropyl Hydrolyzed Collagen, Cocodimonium Hydroxypropyl Hydrolyzed Rice Protein, Cocodimonium Hydroxypropyl Hydrolyzed Silk, Cocodimonium Hydroxypropyl Hydrolyzed Soy Protein, Cocodimonium Hydroxypropyl Hydrolyzed Wheat Protein, Cocodimonium Hydroxypropyl Silk Amino Acids, Hydroxypropyl Arginine Lauryl / Myristyl Ether HCl (substance names are taken from the European Inventory of Cosmetic Ingredients, (COSING)).
Für Haar- und Hautpflegemittel sind konditionierende Stoffe als Zusätze zu dem Mittel besonders geeignet. Hierfür werden beispielsweise Substanzen, die sich an keratinischen Materialien, d.h. der Hornschicht der Haut bzw. der Cuticula des Haarschaftes anlagern und deren physikalische und sensorische Eigenschaften verbessern, verwendet. For hair and skin care products conditioning substances are particularly suitable as additives to the composition. For this purpose, for example, substances that bind to keratinic materials, i. The horny layer of the skin or the cuticle of the hair shaft attach and improve their physical and sensory properties used.
Ebenfalls ist vorgesehen, dass das Mittel Konditionierungsmittel enthalten kann.
Dies ist vorteilhaft, da die Konditionierungsmittel die Oberflächen von Haut und Haaren glätten, beschädigte Areale reparieren und diese weich und geschmeidig halten. It is also envisaged that the agent may contain conditioning agents. This is beneficial because the conditioners smooth the surfaces of the skin and hair, repairing damaged areas and keeping them soft and supple.
Für die Erfindung bevorzugte konditionierende Wirkstoffe sind ausgewählt aus Fettstoffen, insbesondere pflanzlichen Ölen, wie Sonnenblumenöl, Olivenöl, Sojaöl, Rapsöl, Mandelöl, Jojobaöl, Orangenöl, Weizenkeimöl, Pfirsichkernöl und den flüssigen Anteilen des Kokosöls, Lanolin und seinen Derivaten, flüssigen Paraffinölen, Isoparaffinölen und synthetischen Kohlenwasserstoffen, Di-n-alky lethern mit insgesamt 12 bis 36 C- Atomen, beispielsweise Di- n-octylether und n-Hexyl-n-octylether, Fettsäuren, insbesondere lineare und/oder verzweigte, gesättigte und/oder ungesättigte C8-30-Fettsäuren, Fettalkohole, insbesondere gesättigte, ein- oder mehrfach ungesättigte, verzweigte oder unverzweigte Fettalkohole mit 4-30 Kohlenstoffatomen, die mit 1-75, bevorzugt 5-20 Ethylenoxid-Einheiten ethoxyliert und/oder mit 3-30, bevorzugt 9-14 Propylenoxid-Einheiten propoxyliert sind, Esterölen, das heißt Estern von C6-30-Fettsäuren mit C2-30-Fettalkoholen, Hydroxycarbonsäurealkylestern, Dicarbonsäureestern wie Di-n-butyladipat sowie Diolestern wie Ethylenglykoldioleat oder Propylenglykoldi(2-ethylhexanoat), symmetrischen, unsymmetrischen oder cyclischen Estern der Kohlensäure mit Fettalkoholen, wie beispielsweise Glycerincarbonat oder Dicaprylylcarbonat, Mono,-Di- und Trifettsäureestern von gesättigten und/oder ungesättigten linearen und/oder verzweigten Fettsäuren mit Glycerin, die mit zusätzlich 1-10, bevorzugt 7-9 Ethylenoxid-Einheiten ethoxyliert sein können, wie beispielsweise PEG-7 Glyceryl Cocoate, Wachsen, insbesondere Insektenwachsen, Pflanzenwachsen, Fruchtwachsen, Ozokerit, Mikrowachsen, Ceresin, Paraffinwachsen, Triglyceriden gesättigter und gegebenenfalls hydroxylierter C16-30-Fettsäuren, wie beispielsweise gehärtete Triglyceridfette, Phospholipide, beispielsweise Sojalecithin, Ei-Lecithin und Kephalinen, Siliconverbindungen, ausgewählt aus Cyclopentasiloxan, Cyclohexasiloxan und Siliconpolymeren, die bedarfsweise mit weiteren Liganden vernetzt sein können, wie beispielsweise Alkylen, Arylen oder Alkyl- /Arylen, Polyethern von Glycol, Propylenglycol oder Glycerin. For the invention, preferred conditioning agents are selected from fatty substances, especially vegetable oils, such as sunflower oil, olive oil, soybean oil, rapeseed oil, almond oil, jojoba oil, orange oil, wheat germ oil, peach kernel oil and the liquid portions of coconut oil, lanolin and its derivatives, liquid paraffin oils, isoparaffin oils and synthetic hydrocarbons, di-n-alkyl ethers having a total of 12 to 36 carbon atoms, for example di-n-octyl ether and n-hexyl n-octyl ether, fatty acids, in particular linear and / or branched, saturated and / or unsaturated C8-30 Fatty acids, fatty alcohols, in particular saturated, mono- or polyunsaturated, branched or unbranched fatty alcohols having 4-30 carbon atoms, ethoxylated with 1-75, preferably 5-20 ethylene oxide units and / or with 3-30, preferably 9-14 Propylene oxide units are propoxylated, ester oils, that is, esters of C6-30 fatty acids with C2-30 fatty alcohols, Hydroxycarbonsäurealkyle star, dicarboxylic acid esters such as di-n-butyl adipate and diol esters such as ethylene glycol diol or propylene glycol di (2-ethylhexanoate), symmetrical, asymmetrical or cyclic esters of carbonic acid with fatty alcohols such as glycerol carbonate or dicaprylyl carbonate, mono, di- and trifatty acid esters of saturated and / or unsaturated linear and / or branched fatty acids with glycerol, which may be ethoxylated with an additional 1-10, preferably 7-9 ethylene oxide units, such as PEG-7 glyceryl cocoate, waxes, especially insect waxes, plant waxes, fruit waxes, ozokerite, microwaxes, ceresin , Paraffin waxes, triglycerides of saturated and optionally hydroxylated C16-30 fatty acids, such as, for example, hardened triglyceride fats, phospholipids, for example soya lecithin, egg lecithin and cephalins, silicone compounds selected from cyclopentasiloxane, cyclohexasiloxane and silicone polymers, with further ligands as needed may be crosslinked, such as alkylene, arylene or alkyl / arylene, polyethers of glycol, propylene glycol or glycerol.
Weiterhin ist erfindungsgemäß vorgesehen, dass die dem Mittel zugegebenen Komponenten quarternisiert sind. Furthermore, the invention provides that the components added to the agent are quaternized.
Die Einsatzmenge der dafür dem Mittel zugefügten Emolientien und/oder Pflegestoffen soll hierbei in einer Konzentration von 0,1 bis 50,0 Gew.%, vorzugsweise in einer Konzentration
von 0,1 bis 20,0 Gew.% und höchst vorzugsweise in einer Konzentration von 0,1-15,0 Gew.%, jeweils bezogen auf die Rezeptur, vorliegen. The amount used for the Emolientien and / or care agents added to the agent in this case in a concentration of 0.1 to 50.0 wt.%, Preferably in a concentration from 0.1 to 20.0% by weight and most preferably in a concentration of 0.1-15.0% by weight, based in each case on the formulation.
Wegen der Vielfalt in Frage kommender Wirkstoffe, die dem Mittel zugegeben werden können, kann die folgende Aufzählung nur beispielhaft sein und soll im Wesentlichen die möglichen chemischen Strukturen der in Frage kommenden Wirkstoffe verdeutlichen. Because of the variety of candidate drugs that may be added to the agent, the following list may be exemplary only and is intended to clarify substantially the potential chemical structures of the drugs of interest.
Einige der konditionierenden Stoffe, die in dem erfindungsgemäßen Mittel enthalten sind, können instabil in Gegenwart von Sauerstoff sein. Daher ist erfindungsgemäß vorgesehen, dass diese mit Antioxidationsmitteln stabilisiert werden. Some of the conditioning agents included in the composition of the invention may be unstable in the presence of oxygen. Therefore, the invention provides that they are stabilized with antioxidants.
Besonders geeignet sind nachfolgend beispielhaft aufgezählte Komponenten: Particularly suitable below are exemplified enumerated components:
Vorteilhaft werden die Antioxidantien gewählt aus der Gruppe bestehend aus den Aminosäuren (z. B. Glycin, Histidin, Tyrosin, Tryptophan) und deren Derivate, Imidazole (z. B. Urocaninsäure) und deren Derivate, DL-Carnosin, D-Carnosin, L-Carnosin und deren Derivate (z.B. Anserin), Carotinoide, Carotine (z.B. alpha-Carotin, beta-Carotin, Lycopin) und deren Derivate, Chlorogensäure und deren Derivate, Liponsäure und deren Derivate (z.B. Dihydroliponsäure), Aurothioglucose, Propylthiouracil und andere Thiole (z. B. Thioredoxin, Glutathion, Cystein, Cystin, Cystamin und deren Glycosyl-, N-Acetyl-, Methyl-, Ethyl-, Propyl-, Amyl-, Butyl- und Lauryl-, Palmitoyl-, Oleyl-, Linoleylester sowie deren Salze), Dilaurylthiodipropionat, Distearylthiodipropionat, Thiodipropionsäure und deren Derivate (Ester, Ether, Peptide, Lipide, Nukleotide, Nukleoside und Salze) sowie Sulfoximinverbindungen (z.B. Buthioninsulfoximine, Homocysteinsulfoximin, Buthioninsulfone, Penta-, Hexa-, Heptathioninsulfuximin) in sehr geringen verträglichen Dosierungen, ferner (Metall)-Chelatoren (z.B. alpha-Hydroxyfettsäuren, Phytinsäure, Glycosylrutin, Ferulasäure, Furfurylidenglucitol, Butylhydroxytoluol, Butylhydroxyanisol, Nordihydroguaj akharzsäure, Nordihydroguaj aretsäure, Trihydroxybutyrophenon) . Advantageously, the antioxidants are selected from the group consisting of the amino acids (eg, glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg, urocanic acid) and their derivatives, DL-carnosine, D-carnosine, L Carnosine and its derivatives (eg anserine), carotenoids, carotenes (eg alpha-carotene, beta-carotene, lycopene) and their derivatives, chlorogenic acid and its derivatives, lipoic acid and its derivatives (eg dihydrolipoic acid), aurothioglucose, propylthiouracil and other thiols ( For example, thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, linoleyl and their Salts), dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and its derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) as well as sulfoximine compounds (eg buthionine sulfoximines, homocysteinsulfoximine, buthionine sulfones, penta, hexa, heptathionine sulfuxi min) in very low tolerated dosages, also (metal) chelators (e.g. alpha-hydroxy fatty acids, phytic acid, glycosylrutin, ferulic acid, furfurylidene glucitol, butylhydroxytoluene, butylhydroxyanisole, nordihydroguajacic acid, nordihydroguajaretsäure, trihydroxybutyrophenone).
Reinigungsprodukte für Haut oder Haare setzen sich vorzugsweise aus einer Kombination anionischer Tenside, amphoterer, nichtionischer, seltener kationischer Tenside, beispielsweise Fettalkohole der Kettenlänge C10 bis C16, die mit anorganischen Säuren z.B. Phosphor säure, Schwefelsäure oder Essigsäure verestert sind. Zur Verbesserung der Hautverträglichkeit
werden diese Fettsäureester mit Polyethern modifiziert. Geeignete anionische Tenside sind beispielsweise Laurylethersulfat, Laurylsulfat, Myristylsulfat, Laureth Sulfosuccinate, Ethercarboxylate mit variablem Ethoxylierungsgrad, Ethersulfonate auf der Grundlage von Aminosäuren, Zuckern und Fettalkoholen. Cleaning products for the skin or hair are preferably composed of a combination of anionic surfactants, amphoteric, nonionic, more rarely cationic surfactants, for example fatty alcohols of chain length C10 to C16, which are esterified with inorganic acids such as phosphoric acid, sulfuric acid or acetic acid. To improve the skin compatibility These fatty acid esters are modified with polyethers. Suitable anionic surfactants are, for example, lauryl ether sulfate, lauryl sulfate, myristyl sulfate, laureth sulfosuccinates, ether carboxylates with a variable degree of ethoxylation, ether sulfonates based on amino acids, sugars and fatty alcohols.
Es ist vorgesehen, dass diese mit amphoteren Co-Tensiden wie Cocamidopropyl Betaine, Cocoamphodiacetat, ferner Decyl Polyglycoside, Dodecyl Polyglycoside, Trilaureth 4- Phosphate, Di/Mono Sodium Cocoamphoacetate, Acyl-/dialkylethylendiamin, beispielsweise Natriumacylampho acetat, Dinatriumacyl- amphodipropionat, Dinatriumalkylamphodiacetat, Natriumacylamphohydroxy-propylsulfonat, Dinatriumacylamphodiacetat und Natriumacyl- amphopropionat, N-Alkylaminosäuuren, wie beispielsweise Aminopropylalkylglutamid, Alkylamino- Propionsäure, Natriumalkylimidodipropionat und Lauroamphocarboxyglycinat kombiniert werden. It is envisaged that these with amphoteric cosurfactants such as cocamidopropyl betaine, cocoamphodiacetate, furthermore decyl polyglycosides, dodecyl polyglycosides, trilaureth 4-phosphates, di / mono sodium cocoamphoacetate, acyl / dialkylethylenediamine, for example, sodium acylampho acetate, disodium acyl amphodipropionate, disodium alkyl amphodiacetate, Sodium acylamphohydroxypropylsulfonate, disodium acylamphodiacetate and sodium acyl amphopropionate, N-alkylamino acids such as aminopropylalkylglutamide, alkylamino-propionic acid, sodium alkylimidodipropionate and lauroamphocarboxyglycinate.
Hierbei werden die anionischen Tenside bevorzugt in Salzform eingesetzt. Als Kationen kommen Alkali und Erdalkali-Ionen, insbesondere Natrium, Kalium und Magnesium in Frage. In this case, the anionic surfactants are preferably used in salt form. Suitable cations are alkali metal and alkaline earth metal ions, in particular sodium, potassium and magnesium.
Nichtionische Tenside sind beispielsweise Sarcosinate, z.B. Myristoylsarcosinate, TEA- Lauroylsarcosinate, Na-Lauroylsarcosinate, Na-Cocoylsarcosinate, Taurate der Fettsäuren mit einer Kettenlänge von CIO bis C20, gesättigt oder ungesättigt, Acyllysinate, -alaninate oder - glycinate oder Fettalkohol-Polyether mit 10-20 Ethylenoxid oder Propylenoxid- Einheiten. Nonionic surfactants are, for example, sarcosinates, e.g. Myristoyl sarcosinates, TEA lauroyl sarcosinates, Na lauroyl sarcosinates, Na cocoyl sarcosinates, fatty acid having a chain length of C10 to C20, saturated or unsaturated, acyl lysinates, alaninates or glycinates or fatty alcohol polyethers having 10 to 20 ethylene oxide or propylene oxide units.
Kationische Tenside sind in erster Linie die bereits als konditionierende Komponenten beschriebenen quatemierten N- Verbindungen aus der Gruppe der Aminosäuren, Aminozucker oder Peptide. Cationic surfactants are primarily the already described as conditioning components quaternized N compounds from the group of amino acids, amino sugars or peptides.
Weiterhin ist vorgesehen, dass in dem Mittel zur Optimierung des Fließverhaltens Gelbildner enthalten sind. Furthermore, it is provided that gel formers are contained in the means for optimizing the flow behavior.
Gelbildner sind beispielsweise organische Verdickungsmittel, wie beispielsweise Gummi arabicum, Xanthangummi, Natriumalginat, Stärke und Stärkederivate (z. B. Distärkephosphat), Cellulose, Cellulose-Derivate, vorzugsweise Methylcellulose,
Hydroxymethylcellulose, Hydroxyethylcellulose, Hydroxypropylcellulose,Gelling agents are, for example, organic thickeners, such as gum arabic, xanthan gum, sodium alginate, starch and starch derivatives (eg distarch phosphate), cellulose, cellulose derivatives, preferably methyl cellulose, Hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose,
Hydroxypropylmethylcellulose oder anorganische Verdickungmittel, wie beispielsweise Aluminiumsilikate, wie beispielsweise organisch modifizierte oder auch unmodifizierte Hectorite, Bentonite, oder dergleichen, oder ein Gemisch aus Polyethylenglykol und Polyethylenglykolstearat oder -distearat. Weiterhin sind Biopolymere wie zum Beispiel Chitin oder Chitin-Derivate oder Poly-Glucuron- oder Polygalacturonsäuren und deren Amide geeignet. Eine weitere Gruppe besonders effektiver Gele besteht aus modifizierten Polymeren der Acrylsäure. Hydroxypropylmethylcellulose or inorganic thickening agents, such as aluminum silicates, such as organically modified or unmodified hectorites, bentonites, or the like, or a mixture of polyethylene glycol and polyethylene glycol stearate or distearate. Furthermore, biopolymers such as chitin or chitin derivatives or poly-glucuronic or polygalacturonic acids and their amides are suitable. Another group of particularly effective gels consists of modified polymers of acrylic acid.
Es ist weiterhin vorgesehen, dass das Verdickungsmittel in dem Gel in einer Konzentration von 0,1 bis 30,0 Gew.- , vorzugsweise in einer Konzentration von 0,5 bis 15,0 Gew.- , enthalten ist. It is further contemplated that the thickener is contained in the gel in a concentration of 0.1 to 30.0 parts by weight, preferably in a concentration of 0.5 to 15.0 parts by weight.
Rezepturen zur Haut und Haarpflege bestehen maßgeblich aus Ölen und Pflegestoffen, die in wässrigen Systemen mittels Emulgatoren stabilisiert werden müssen. Prescriptions for the skin and hair care mainly consist of oils and care substances, which have to be stabilized in aqueous systems by means of emulsifiers.
Daher ist erfindungsgemäß vorgesehen, dass das Mittel Emulgatoren enthält. Therefore, the invention provides that the agent contains emulsifiers.
Geeignete Emulgatoren sind z.B. PEG-n hydriertes Ricinusöl, PEG-n Caprylsäure/Caprinsäureglyceride, Glyceryloleat im Gemisch mit Propylenglycol, PEG-n- Stearat, Ceteth-n, Ceteth-n, Polysorbat n, Glycerylstearat im Gemisch mit PEG-n, Glycerylmyristat, Glyceryllaurat, PEG-n- Sorbitanperoleat, Laureth-n, Ceteareth-n, Isostearylglycerylether, Cetylstearylalkohol im Gemisch mit Natrium Cetylstearylsulfat, Lameth-n, Steareth-n, Glycerylstearat im Gemisch mit PEG-n Stearat. PEG-n-Stearat, Glycol Distearat, PEG-n-Dodecyl Glycol, Polyglyceryl-n PEG-n-Stearat, Ceteareth-n, Methylglucosesesquistearat, Steareth-n, PEG-n-Stearat, Steareth-n im Gemisch mit PEG-n Distearat, Steareth-n, Steareth-n, Isosteareth-n, PEG-n Dodecyglycol-Copolymer, Methoxy- PEG-n Dodecylglycol-Copolymer, PEG-n-Sorbitanperoleat, PEG-n-Sorbitanperisostearat, PEG-n-Glycerylstearat, PEG-n-Glycerylstearat, PEG-n-Bienenwachs, Polyglyceryl-n-laurat, Isostearyldiglycerylsuccinat, Stearamidopropyl-PG-dimoniumchloridphosphat, Glycerylstearat SE, PEG-n-Methylglucosesesquistearat, Ceteareth-n, Glycerylstearatcitrat, Cetylphosphat, Sorbitansesquioleat, Trilaureth-n-Phosphat, Polyglycerylglucosedistearat, Kaliumcetylphosphat, Isosteareth-n, Polyglyceryl-n-sesquiisostearat, Ceteth-n, Oleth-n,
Isoceteth-n, Glycerylsterat im Gemisch mit Ceteareth-n, Ceteareth-n, Cetylstearylalkohol und Cetylpalmitat, Cetylstearylalkohol im Gemisch mit PEG-n-Stearat, PEG-n-Stearat, PEG-n- Stearat, PEG-n-Stearat, wobei n die Zahl der Etherverbindungen darstellt und 2 bis 100 betragen kann. Suitable emulsifiers are, for example, PEG-n hydrogenated castor oil, PEG-n caprylic acid / capric acid glycerides, glyceryl oleate mixed with propylene glycol, PEG-n-stearate, ceteth-n, ceteth-n, polysorbate n, glyceryl stearate in admixture with PEG-n, glyceryl myristate, Glyceryl laurate, PEG-n-sorbitan peroleate, laureth-n, ceteareth-n, isostearyl glyceryl ether, cetylstearyl alcohol in admixture with sodium cetyl stearyl sulfate, lameth-n, steareth-n, glyceryl stearate in admixture with PEG-n stearate. PEG-n-stearate, glycol distearate, PEG-n-dodecyl glycol, polyglyceryl-n-PEG-n-stearate, ceteareth-n, methyl glucose sesquistearate, steareth-n, PEG-n-stearate, steareth-n in admixture with PEG-n Distearate, steareth-n, steareth-n, isosteareth-n, PEG-n dodecyglycol copolymer, methoxy-PEG-n dodecyl glycol copolymer, PEG-n sorbitan peroleate, PEG-n sorbitan perisostearate, PEG-n-glyceryl stearate, PEG- n-glyceryl stearate, PEG-n beeswax, polyglyceryl n-laurate, isostearyl diglyceryl succinate, stearamidopropyl PG-dimonium chloride phosphate, glyceryl stearate SE, PEG-n-methyl glucose sesquistearate, ceteareth-n, glyceryl stearate citrate, cetyl phosphate, sorbitan sesquioleate, trilaureth-n-phosphate, polyglyceryl glucose distearate , Potassium cetyl phosphate, isosteareth-n, polyglyceryl-n-sesquiisostearate, ceteth-n, oleth-n, Isoceteth-n, glyceryl stearate in admixture with ceteareth-n, ceteareth-n, cetylstearyl alcohol and cetyl palmitate, cetylstearyl alcohol in admixture with PEG-n-stearate, PEG-n-stearate, PEG-n-stearate, PEG-n-stearate, where n represents the number of ether compounds and can be 2 to 100.
Damit das erfindungsgemäße Mittel mit den vorgenannten enthaltenden Wirkstoff- Kombinationen bestmöglich auf der Oberfläche von Haut oder Haaren, Gastrointestinal- oder Respirationstrakt bzw. Vaginalbereich verteilt werden kann, ist eine spezifische galenische Formulierung notwendig. Diese richtet sich nach individuellen Bedürfnissen des Anwenders. So that the agent according to the invention can be best distributed on the surface of skin or hair, gastrointestinal or respiratory tract or vaginal area with the abovementioned active ingredient combinations, a specific galenic formulation is necessary. This depends on the individual needs of the user.
Es ist vorteilhaft, dass das erfindungsgemäße Mittel für dermatologische Anwendungen in Form einer flüssigen, fließfähigen oder festen Öl-in- Wasser-Emulsion, Wasser-in-Öl- Emulsion, Mehrfach-Emulsion, insbesondere einer Öl-in- Wasser-in-Öl- oder Wasser-in-Öl- in- Wasser-Emulsion, Makroemulsion, Mikroemulsion, PIT-Emulsion, Nanoemulsion, Hydrodispersion, eines Hydrogels, eines Lipogels, einer ein- oder mehrphasigen Lösung, eines Schaumes, einer wässig-alkoholischen Lösung oder einer Tensidformulierung vorliegt. It is advantageous that the agent according to the invention for dermatological applications in the form of a liquid, flowable or solid oil-in-water emulsion, water-in-oil emulsion, multiple emulsion, in particular an oil-in-water-in-oil or water-in-oil-in-water emulsion, macroemulsion, microemulsion, PIT emulsion, nanoemulsion, hydrodispersion, hydrogel, lipogel, mono- or multiphase solution, foam, aqueous-alcoholic solution or surfactant formulation is present.
Für den Respirationstrakt, insbesondere der Nase, ist vorgesehen, dass das Mittel mit Applikatoren, wie beispielsweise Dosierspitzen oder Sprüh-Dosierern in Form wässrig, wässrig-alkoholischer Lösungen, Lotionen oder Gele applizierbar ist. For the respiratory tract, especially the nose, it is provided that the agent with applicators, such as dosing tips or spray dosing in the form of aqueous, aqueous-alcoholic solutions, lotions or gels is administered.
Es ist weiterhin für Hautpflegemittel, sogenannte Kuren und Packungen, Hautschutzcremes, Sonnenschutzlotion, Nährcremes, Tages- bzw. Nachtcremes oder Ampullen vorgesehen, dass diesen das erfindungsgemäße Mittel beigefügt ist. It is further provided for skin care products, so-called cures and packs, skin protection creams, sunscreen lotion, nutrient creams, day creams or night creams or ampoules, that these means of the invention is attached.
Es ist weiterhin für Deo- oder Antitranspirantprodukte vorgesehen, dass das erfindungsgemäße Mittel für Sprays, Roll-Ons und Deocremes verwendet wird. It is further provided for deodorant or antiperspirant products that the agent according to the invention is used for sprays, roll-ons and deodorants.
Für Haut- bzw. Haar-Reinigungsmittel, die das erfindungsgemäße Mittel beinhalten, sind beispielsweise Seifen, Reinigungsmilchen, Reinigungsgele, Shampoos, Schäume, Reinigungssprays, Spülungen, Kuren, alkoholische Lotionen, Haarcremes oder Kopfhautwässer vorgesehen.
Die folgenden Formulierungsbeispiele sollen den Gegenstand der Erfindung verdeutlichen, ohne ihn hierauf zu beschränken. Alle Angaben sind in Gew.- bezogen auf die gesamte Zusammensetzung. Die Stoffbezeichnungen sind dem verbindlichen Inventar kosmetischer Inhaltsstoffe, COSING, entnommen. For skin or hair cleansers containing the agent according to the invention, for example, soaps, cleansing gels, cleansing gels, shampoos, foams, cleansing sprays, rinses, cures, alcoholic lotions, hair creams or scalp waters are provided. The following formulation examples are intended to illustrate the subject matter of the invention without limiting it thereto. All data are in parts by weight based on the total composition. The substance names are taken from the binding inventory of cosmetic ingredients, COSING.
Mildes Haar- und Körpershampoo (Angaben in Gewichtsprozent) Mild hair and body shampoo (by weight)
Xanthan Gum 1,00 Xanthan Gum 1.00
Coco Glucoside 2,00 Coco Glucoside 2.00
Sodium Cocoyl Alaninate 5,00 Sodium cocoyl alaninate 5.00
Sodium Myristate 10,00 Sodium myristate 10.00
Glycerin 0,20 Glycerol 0.20
Adenine 0,30 Adenine 0.30
Citric Acid 0,50 Citric Acid 0.50
Caffeine 1,00 Caffeine 1.00
Potassium Sorbate 0,20 Potassium sorbate 0.20
Aqua ad 100 Aqua ad 100
Anti-Schuppen-Shampoo (Angaben in Gewichtsprozent) Anti-dandruff shampoo (in% by weight)
Sodium Cocoyl Alaninate 7,00 Sodium cocoyl alaninate 7.00
Sodium Laureth Sulfate 11,00 Sodium Laureth Sulfate 11.00
Cocamidopropyl Betaine 29,00 Cocamidopropyl Betaine 29.00
Glycerin 5,00 Glycerin 5.00
Theobromine 2,00 Theobromine 2.00
Zinc Pyrithione 0,80 Zinc Pyrithione 0.80
Zinc PCA 2,00 Zinc PCA 2.00
Polysorbate 20 1,00 Polysorbate 20 1.00
Parfüm 0,20 Perfume 0.20
Panthenol 0,50 Panthenol 0.50
Methylpropanediol, Caprylyl Glycol, Methylpropanediol, caprylyl glycol,
Phenyl Propanol 3,00 Phenylpropanol 3.00
Aqua ad 100
Deo-Creme (Angaben in Gewichtsprozent) Aqua ad 100 Deodorant cream (in percent by weight)
Isohexadecane 5,00Isohexadecane 5.00
Ethylhexyl Stearate 8,00Ethylhexyl Stearate 8.00
Decyl Oleate 6,00Decyl Oleate 6,00
Phenoxyethanol 0,60Phenoxyethanol 0.60
Ethylhexylglycerin 0,40Ethylhexylglycerol 0.40
Sorbitan Oleate 3,00Sorbitan Oleate 3.00
Polyglyceryl-3 Polyricinoleate 2,00Polyglyceryl-3 Polyricinoleate 2.00
Sucrose Polystearate 1,00Sucrose polystearate 1.00
Theophylline 0,10Theophylline 0.10
Tocopheryl Acetate 1,00Tocopheryl acetate 1.00
Magnesium Sulfate 0,70Magnesium Sulfate 0,70
Glycerin 5,00Glycerin 5.00
Parfüm 0,30Perfume 0.30
Octyldodecanol 2,00Octyldodecanol 2.00
Aqua ad 100 Aqua ad 100
Gesichtscreme (Angaben in Gewichtsprozent) Face cream (in percent by weight)
Pectin 0,50Pectin 0.50
Glycerin 3,00Glycerol 3.00
Carbomer 0,20Carbomer 0.20
Glyceryl Stearate Citrate 3,00Glyceryl Stearate Citrate 3.00
Sucrose Stearate 1,00Sucrose stearate 1.00
Cetearyl Alcohol 1,50Cetearyl Alcohol 1.50
Ethylhexyl Palmitate 9,00Ethylhexyl palmitate 9.00
Isoamyl Laurate 6,00Isoamyl Laurate 6.00
Helianthuus Annuus Seed Oil Helianthuus Annuus Seed Oil
Unsaponifiables 2,00 Unsaponifiables 2.00
Tocopherol, 0,20Tocopherol, 0.20
Caffeine 0,30Caffeine 0.30
Helianthus Annuus Seed Oil 2,00Helianthus Annuus Seed Oil 2.00
Theobromine 0,20Theobromine 0.20
Phenoxyethanol 0,80Phenoxyethanol 0.80
Ethylhexylglycerin 1,00Ethylhexylglycerol 1.00
Arginine 0,30Arginine 0.30
Parfüm 0,20Perfume 0.20
Xanthan Gum 0,25Xanthan gum 0.25
Sodium Hydroxide 0,10Sodium hydroxides 0.10
Aqua ad 100
Fuss-Gel (Angaben in Gewichtsprozent) Aqua ad 100 Foot gel (in percent by weight)
Aqua ad 100 Aqua ad 100
Glycerin 4,00Glycerol 4.00
Phenoxyethanol, 0,50Phenoxyethanol, 0.50
Ethylhexylglycerin 2 0,50Ethylhexylglycerol 2 0.50
Carbomer 0,15Carbomer 0.15
Farnesol 0,50Farnesol 0.50
1 -Methylxanthine 0,201-methylxanthines 0.20
Zink PCA 0,30Zinc PCA 0.30
Acrylates/C10-30 Alkyl Acrylate Acrylates / C10-30 alkyl acrylates
Crosspolymer 0,25 Crosspolymer 0.25
Sodium Hydroxide 0,10Sodium hydroxides 0.10
Alcohol 3,00Alcohol 3.00
Theophylline 2,00 Theophylline 2.00
Kopfhaut-Tonikum (Angaben in GewichtsprozentScalp tonic (in percent by weight
Aqua ad 100Aqua ad 100
Glycerin 0,20Glycerol 0.20
Alcohol 40,00Alcohol 40,00
Panthenol 0,30Panthenol 0.30
Carbomer 0,15Carbomer 0.15
Farnesol 0,10Farnesol 0.10
Xanthine 0,20Xanthines 0.20
Biotin 0,01Biotin 0.01
Acrylates/C10-30 Alkyl Acrylate Acrylates / C10-30 alkyl acrylates
Crosspolymer 0,10 Crosspolymer 0.10
Sodium Hydroxide 0,01Sodium hydroxides 0.01
Magnesium Gluconate 0,20 Magnesium gluconate 0.20
Mundwasser (Angaben in Gewichtsprozent)Mouthwash (in% by weight)
Aqua ad 100Aqua ad 100
Glycerin 10,00Glycerin 10.00
Alcohol 10,00Alcohol 10.00
Sodium Phosphate 1,00Sodium Phosphates 1.00
Xylitol 0,15Xylitol 0.15
1 -Methylxanthine 0,101-methylxanthines 0.10
Aroma 0,20Aroma 0.20
Menthol 0,01Menthol 0.01
CI 42090 0,01CI 42090 0,01
Potassium Sorbate 0,10Potassium Sorbate 0.10
Sodium Benzoate 0,05
Sodium Benzoate 0.05
Claims
1. Verwendung eines Mittels zur Stimulation der Expression antimikrobieller Peptide (AMP), wobei das Mittel ein Purin oder ein Purinalkaloid, letzteres ausgewählt aus der Gruppe bestehend aus Xanthin, Theobromin, Paraxanthin, Theophyllin, 3-Isobutyl-l- methylxanthin (IBMX) und 1-Methylxanthin enthält. Use of an agent for stimulating the expression of antimicrobial peptides (AMP), wherein the agent is a purine or a purine alkaloid, the latter selected from the group consisting of xanthine, theobromine, paraxanthin, theophylline, 3-isobutyl-l-methylxanthine (IBMX) and Contains 1-methylxanthine.
2. Verwendung eines Mittels gemäß Anspruch 1, 2. Use of an agent according to claim 1,
dadurch gekennzeichnet, dass das antimikrobielle Peptid (AMP) Dermcidin (DCD) ist. characterized in that the antimicrobial peptide (AMP) is dercidin (DCD).
3. Verwendung eines Mittels gemäß Anspruch 2, 3. Use of an agent according to claim 2,
dadurch gekennzeichnet, dass das Dermcidin das anionische DCD-1L ist. characterized in that the dercidin is the anionic DCD-1L.
4. Verwendung eines Mittels gemäß Anspruch 1, 4. Use of a composition according to claim 1,
dadurch gekennzeichnet, dass das Mittel enteral, intragastral, inhalativ, intranasal, vaginal, kutan oder topisch anwendbar ist. characterized in that the agent is enteral, intragastric, inhalative, intranasal, vaginal, cutaneous or topically applicable.
5. Verwendung eines Mittels gemäß Anspruch 1, 5. Use of an agent according to claim 1,
dadurch gekennzeichnet, dass das Mittel ein kosmetisches Mittel ist. characterized in that the agent is a cosmetic agent.
6. Verwendung eines Mittels gemäß Anspruch 5, 6. Use of a composition according to claim 5,
dadurch gekennzeichnet, dass das kosmetische Mittel in Form eines Haarbehandlungsmittels, insbesondere Spülungen, Kuren, Pflegecremes, Reinigungsmittel, Haartonics, Kopfhautlösungen, Shampoos, Festiger, Gele, Schäume oder in Form eines Hautbehandlungsmittels, insbesondere Hautcremes, Masken, Packungen, Waschemulsionen, Waschgelen, wässrige alkoholische, tonische Lösungen, Seren, Hautgele, Lotionen, Fluids, Deo- oder Antitranspiranzprodukte oder in Form eines Behandlungsmittels für die Mundhöhle, insbesondere Mundwässer und Salben vorliegt. characterized in that the cosmetic agent is in the form of a hair treatment agent, in particular rinses, cures, care creams, cleansers, hair tonics, scalp solutions, shampoos, fixatives, gels, foams or in the form of a skin treatment agent, in particular skin creams, masks, packs, wash emulsions, wash gels, aqueous alcoholic, tonic solutions, serums, skin gels, lotions, fluids, deodorant or antiperspirant products or in the form of a treatment agent for the oral cavity, in particular mouthwashes and ointments.
7. Verwendung eines Mittels gemäß Anspruch 1, 7. Use of an agent according to claim 1,
dadurch gekennzeichnet, dass das Mittel ein pharmazeutisches Mittel ist. characterized in that the agent is a pharmaceutical agent.
8. Verwendung eines Mittels gemäß Anspruch 1, 8. Use of an agent according to claim 1,
dadurch gekennzeichnet, dass das Mittel Koffein enthält. characterized in that the agent contains caffeine.
9. Verwendung eines Mittels gemäß Anspruch 1, 9. Use of an agent according to claim 1,
dadurch gekennzeichnet, dass das Mittel biozide Wirkstoffe, ausgewählt aus der Gruppe bestehend aus Zinkverbindungen, insbesondere Zink Pyrithion, Zink- Ricinoleate, Zink-PCA oder anorganische Zinksalze, halogenorganischen Verbindungen, insbesondere 2,4,4'-Trichlor-2'- hydroxydiphenylether (Irgasan), 1,6- Di-(4-chlorphenylbiguanido)-hexan (Chlorhexidin), 3,4,4'-'Trichlorcarbanilid, Polyalkohole, insbesondere Nelkenöl, Minzöl, Thymianöl, Triethylcitrat, Farnesol (3,7,1 l-Trimethyl-2,6,10-dodecatrien-I-ol) enthält. characterized in that the agent biocidal agents selected from the group consisting of zinc compounds, in particular zinc pyrithione, zinc ricinoleates, zinc PCA or inorganic zinc salts, organohalogen compounds, in particular 2,4,4'-trichloro-2'-hydroxydiphenyl ether ( Irgasan), 1,6-di- (4-chlorophenylbiguanido) hexane (chlorhexidine), 3,4,4 '-' trichlorocarbanilide, polyalcohols, especially clove oil, mint oil, thyme oil, triethyl citrate, farnesol (3,7,1 l- Trimethyl-2,6,10-dodecatrien-1-ol).
10. Verwendung eines Mittels gemäß Anspruch 1, 10. Use of an agent according to claim 1,
dadurch gekennzeichnet, dass das Mittel antiinflammatorische Wirkstoffe, insbesondere ausgewählt aus der Gruppe bestehend aus Bisabolol, Panthenol und Tocopherol enthält. characterized in that the agent contains anti-inflammatory agents, in particular selected from the group consisting of bisabolol, panthenol and tocopherol.
11. Verwendung eines Mittels gemäß Anspruch 1, 11. Use of a composition according to claim 1,
dadurch gekennzeichnet, dass das Mittel Pflanzenextrakte, insbesondere ausgewählt aus der Gruppe bestehend aus Echinacea, Ferula, Calendula und Melaleuca enthält. characterized in that the agent contains plant extracts, in particular selected from the group consisting of Echinacea, Ferula, Calendula and Melaleuca.
12. Verwendung eines Mittels gemäß Anspruch 1, 12. Use of an agent according to claim 1,
dadurch gekennzeichnet, dass das Purin und/oder Purinalkaloid als Derivat vorliegt. characterized in that the purine and / or Purinalkaloid is present as a derivative.
13. Verwendung eines Mittels gemäß Anspruch 1, 13. Use of an agent according to claim 1,
dadurch gekennzeichnet, dass das Purin und/oder Purinalkaloid in einer Konzentration von 0,001 bis 10 Gew.- , vorzugsweise in einer Konzentration von 0,01 bis 5,0 Gew.- , höchst vorzugsweise in einer Konzentration von 0,1 bis 2,0 Gew.- vorliegt. characterized in that the purine and / or purine alkaloid in a concentration of 0.001 to 10 parts by weight, preferably in a concentration of 0.01 to 5.0 parts by weight, most preferably in a concentration of 0.1 to 2.0 Gew.- present.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102012002592A DE102012002592A1 (en) | 2012-02-13 | 2012-02-13 | Use of an agent for stimulating the gene expression of antimicrobial peptides (AMP) |
DE102012002592.0 | 2012-02-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013120481A2 true WO2013120481A2 (en) | 2013-08-22 |
WO2013120481A3 WO2013120481A3 (en) | 2014-09-18 |
Family
ID=47842985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2013/100038 WO2013120481A2 (en) | 2012-02-13 | 2013-02-05 | Use of an agent for stimulating the gene expression of antimicrobial peptides (amp) |
Country Status (2)
Country | Link |
---|---|
DE (1) | DE102012002592A1 (en) |
WO (1) | WO2013120481A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3120850A1 (en) * | 2012-12-14 | 2017-01-25 | Unilever N.V. | Niacinamide for inducing generation of antimicrobial peptides |
WO2017173236A1 (en) * | 2016-03-31 | 2017-10-05 | Gojo Industries, Inc. | Antimicrobial peptide stimulating sanitizing composition |
US10806769B2 (en) | 2016-03-31 | 2020-10-20 | Gojo Industries, Inc. | Antimicrobial peptide stimulating cleansing composition |
US10874700B2 (en) | 2016-03-31 | 2020-12-29 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
WO2022217000A1 (en) * | 2021-04-07 | 2022-10-13 | Ingenious Ingredients, LP | 1-methylxanthine-based bioactive composition and method of use thereof |
US11564879B2 (en) | 2016-11-23 | 2023-01-31 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA031758B1 (en) * | 2014-05-12 | 2019-02-28 | Юнилевер Н.В. | Niacinamide for inducing generation of antimicrobial peptides |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2382528A (en) | 2001-11-12 | 2003-06-04 | Mars Inc | Consumable composition for the development of a healthy gastrointestinal tract |
DE102004032734A1 (en) | 2004-03-18 | 2005-10-06 | Henkel Kgaa | Prebiotic substances for deodorants |
DE102005014687A1 (en) | 2005-03-29 | 2006-10-12 | Henkel Kgaa | Composition containing β-defensin 2 |
DE60119669T2 (en) | 2000-11-16 | 2007-05-16 | Johnson & Johnson Consumer France Sas | Caprylylglycol and Iodopropynylbutylcarbamate containing compositions |
DE102009027604A1 (en) | 2009-07-10 | 2011-01-20 | Henkel Ag & Co. Kgaa | Cosmetic compositions with suspensions of silver salts |
EP2277524A1 (en) | 2005-09-28 | 2011-01-26 | Nordisk Rebalance A/S | Treatment of IBD and IBS using both probiotec bacteria and fermented cereal as treatment effectors |
DE102010027947A1 (en) | 2010-04-20 | 2011-10-20 | Henkel Ag & Co. Kgaa | Skin-friendly deodorants and antiperspirants |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200533333A (en) * | 2004-02-17 | 2005-10-16 | Otsuka Pharma Co Ltd | Human beta-defensin production accelerator |
JP2010270030A (en) * | 2009-05-20 | 2010-12-02 | Fukuoka Univ | Antibacterial peptide expression inducer or secretagogue |
-
2012
- 2012-02-13 DE DE102012002592A patent/DE102012002592A1/en not_active Ceased
-
2013
- 2013-02-05 WO PCT/DE2013/100038 patent/WO2013120481A2/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60119669T2 (en) | 2000-11-16 | 2007-05-16 | Johnson & Johnson Consumer France Sas | Caprylylglycol and Iodopropynylbutylcarbamate containing compositions |
GB2382528A (en) | 2001-11-12 | 2003-06-04 | Mars Inc | Consumable composition for the development of a healthy gastrointestinal tract |
DE102004032734A1 (en) | 2004-03-18 | 2005-10-06 | Henkel Kgaa | Prebiotic substances for deodorants |
DE102005014687A1 (en) | 2005-03-29 | 2006-10-12 | Henkel Kgaa | Composition containing β-defensin 2 |
EP2277524A1 (en) | 2005-09-28 | 2011-01-26 | Nordisk Rebalance A/S | Treatment of IBD and IBS using both probiotec bacteria and fermented cereal as treatment effectors |
DE102009027604A1 (en) | 2009-07-10 | 2011-01-20 | Henkel Ag & Co. Kgaa | Cosmetic compositions with suspensions of silver salts |
DE102010027947A1 (en) | 2010-04-20 | 2011-10-20 | Henkel Ag & Co. Kgaa | Skin-friendly deodorants and antiperspirants |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3120850A1 (en) * | 2012-12-14 | 2017-01-25 | Unilever N.V. | Niacinamide for inducing generation of antimicrobial peptides |
WO2017173236A1 (en) * | 2016-03-31 | 2017-10-05 | Gojo Industries, Inc. | Antimicrobial peptide stimulating sanitizing composition |
US10806769B2 (en) | 2016-03-31 | 2020-10-20 | Gojo Industries, Inc. | Antimicrobial peptide stimulating cleansing composition |
US10874700B2 (en) | 2016-03-31 | 2020-12-29 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
US11633451B2 (en) | 2016-03-31 | 2023-04-25 | Gojo Industries, Inc. | Antimicrobial peptide stimulating cleansing composition |
US11998575B2 (en) | 2016-03-31 | 2024-06-04 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
US11564879B2 (en) | 2016-11-23 | 2023-01-31 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
WO2022217000A1 (en) * | 2021-04-07 | 2022-10-13 | Ingenious Ingredients, LP | 1-methylxanthine-based bioactive composition and method of use thereof |
Also Published As
Publication number | Publication date |
---|---|
DE102012002592A1 (en) | 2013-08-14 |
WO2013120481A3 (en) | 2014-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2174648B1 (en) | Skin-care compositions and uses thereof | |
ES2243901T3 (en) | STABILIZED ASCORBIC ACID DERIVATIVES. | |
WO2013120481A2 (en) | Use of an agent for stimulating the gene expression of antimicrobial peptides (amp) | |
JPWO2004016236A1 (en) | Cosmetics | |
EP3436158B1 (en) | Topical composition comprising plant extracts | |
KR101015702B1 (en) | Composition for improving and alleviating inflammation and skin irritation, including seaweed extract | |
DE102006060439A1 (en) | Cosmetic or dermatological composition for treating e.g. cellulite contains hyperemisating active ingredients and active ingredients for reducing the degranulation of mast cells and/or for releasing histamine | |
JP6505905B2 (en) | Cosmetics of catechin fatty acid derivatives | |
KR100947638B1 (en) | Composition containing lava sea salt | |
US20170367954A1 (en) | Composition including ionone or salt thereof as active ingredient and having effect of enhancing skin moisturizing, exfoliating skin, improving skin elasticity, inhibiting erythema, improving skin wrinkles, or alleviating skin photoaging | |
US20210361559A1 (en) | Composition containing cirsium japonicum extract as active ingredient for stimulating melanogenesis | |
KR101796866B1 (en) | Composition having effects of skin moisturizing, exfoliating, improving skin elasticity, inhibiting erythema, anti-wrinkle or improving skin photoaging comprising at least one selected from the group consisting of cymene, behenic acid, 2-methoxynaphthalene, thymol and salts thereof | |
KR20200043406A (en) | Whitening agents, external preparations for skin whitening and methods for whitening skin | |
DE19634019A1 (en) | Antimicrobial, antiviral, antiparasitic and antiprotozoal agents | |
EP3615147B1 (en) | Yarrow fresh-plant pressed juice concentrate, production, and use | |
EP1539128B1 (en) | Use of skin-protecting substances | |
EP2100593B1 (en) | Ternary mixtures with increased collagen synthesis | |
KR101419588B1 (en) | Composition for Moisturizing Skin Comprising Ginseng Oil as Active Ingredient | |
KR102626479B1 (en) | Gentiana extract without gentiopicroside | |
EP2090296B1 (en) | Application of agent complexes composed of panthenol, glycerin, citrate and/or bisabal oil against pollen allergy | |
EP1094787A1 (en) | Preparations for protecting infants' skin against diaper dermatitis | |
CN112912054A (en) | Composition for skin barrier enhancement | |
JP2020189816A (en) | Vitamin C derivative composition | |
CN112912053A (en) | Composition for skin barrier enhancement | |
KR20210036166A (en) | Composition for skin barrier |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13708072 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13708072 Country of ref document: EP Kind code of ref document: A2 |